Characterisation of the metastasis-inducible calcium-binding S100P protein on cell activity by Attignon, ValÃ©ry Kossi Wodadje
UNIVERSITY OF
LIVERPOOLeepmby    
Characterisation of the Metastasis-Inducible
Calcium-binding S100P protein oncell activity
Thesis submitted in accordance with the requirements of the University of
Liverpool for the degree of Doctor in Philosophy
Valéry Kossi Wodadje ATTIGNON
December 2010
Acknowlegdements
I must thank first and foremost my supervisors Roger Barraclough and
Philip Rudlandfor all their guidance andinspiration throughout mystudies.
Manythanks to all my colleagues for their company, useful discussions and
delicious cakes.
Table of Contents
Abstract
List of Figures
List of Tables
List of Abbreviations
Chapter 1 Introduction
1.1 S100 protein family
1.1.1 History
1.1.2 Structure
1.1.3 Functions
1.4 $100s, Cancer and Metastasis
1.2. S100P
1.2.1 Structure
1.2.2 S100P in Cancer, Role and Function
1.2.3. Regulation of S100P expression
1.2.4 Targets for interaction of S100P
1.2.5 Subcellular localisation and tissue distribution of S100P
1.2.6 S100P possesses an unknown nuclear modeofaction for
metastasis
1.3. Aim of Project
Chapter 2 Materials and Methods
2.1. MATERIALS
2.1.1. Chemicals and Biochemicals
2.1.2. Kits
2.1.3. Other Materials
2.1.4. Solutions
ao
a
n
o
NY
ND
11
13
16
17
18
18
21
22
23
23
24
Zo
25
2.1.4.1. Solutions
2.1.4.2. Medium and Antibiotics for Cell Culture
2.1.4.3. Western Blot Solutions
2.1.5. Primers
2.1.5.1. Primers for quantitative real-time PCR
2.1.6. SIRNA Sequences
2.1.7. Antibodies
2.1.7.1. Antibodies used in Western blot
2.1.7.2. Immunostaining Antibodies
2.1.7.3. Other
2.1.8. Cell Culture
2.1.8.1. Cell lines
2.1.8.2. Vectors
2.1.8.3. Transfection Reagents
2.1.8.4. Inhibitors
2.1.9. Instruments
2.1.10.Software for data handling
2.1. METHODS
2.2.1. Tissue culture
2.2.1.1. Cell culture
2.2.1.1.a. Cell lines used
2.2.1.1.b. Routine culture
2.2.1.1.c. Routine passagingofcells
2.2.1.1.d. Freezing cells
2.2.1.1.e. Thawingcells
2.2.1.1.f. Counting cells
2.2.1.1.g. Treatmentofcells
2.2.1.2. Cell migration
2.2.1.3. Characterisation of cell adhesion andproliferation
2.2.1.3.a. Cell adhesion assay
2.2.1.4. Analysis of cell lines
2.2.1.4.a. Immunohistochemicalstaining
2.2.1.4.b. Immunofluorescence
25
26
27
29
29
31
31
31
32
32
33
33
33
33
33
34
34
35
35
35
35
36
36
37
37
37
38
38
40
40
40
40
41
2.2.2. Protein blotting techniques
2.2.2.1.Protein extraction
2.2.2.2. Denaturing polyacrylamide gel electrophoresis
(SDS-PAGE)
2.2.2.3. Coomassie blue staining of separated
polypeptides after SDS-PAGE
2.2.2.4. Western blotting
2.2.2.5. S100P immunoprecipitation
2.2.3. Manipulation of DNA
2.2.4. Manipulation of RNA
2.2.4.1. Isolation of RNA
2.2.4.2. RNA clean-up
2.2.4.3. Determination of RNA concentration
2.2.4.4. Microarray analysis of differential mRNA
expression
2.2.5. Polymerase chain reaction
2.2.5.1. Reverse transcription
2.2.5.2. Polymerase chain reaction
2.2.5.3. Quantitative real-time Polymerase Chain Reaction
2.2.5.4. SIRNA
2.2.5.5. Statistical analysis
Chapter 3 Identification of S100P as a Protein
Associated with Increased Cell Migration
3.1 Introduction
3.2.Results
3.2.1. Induction of S100P protein
3.2.2. Intracellular S100P stimulates cell migration in vitro
3.2.2.1. Rat mammary cells
3.2.2.2. Human cells
3.2.3. Intracellular Distribution of S100P
4
A
42
42
42
43
43
44
44
44
45
45
47
47
48
48
49
50
51
52
54
54
63
63
66
68
3.2.3.1. Subcellular distribution of induced S100P
3.2.4. Discussion
Chapter 4 Epigenetic Modification/Regulation by
Overexpression of S100P
4.1. Introduction
4.2. Results
4.2.1. Identification of genes associated with S100P
overexpression by DNA chip microarray
4.2.2. Validation of microarray results
4.2.3. Treatment with Mast1 specific SIRNA decreasesin vitro
cell migration in Rama 37 cells overexpressing S100P
4.2.4. Effects of MAST1 mRNA knock-down oncell migration
4.3. Discussion
Chapter 5 The Extracellular role of S100P
5.1. Introduction
5.2. Results
5.2.1. S100P can translocate outside of cells
5.2.2. Extracellular role of S100P
5.2.2.1. Extracellular S100P can stimulate cell migration
5.2.2.2. Addition of Extracellular S100P stimulates the
AKT signalling pathway
5.2.2.3. Addition of extracellular S100P stimulates
the ERK 1/2 signalling pathway
5.2.2.4. S100P mediated PI3K/AKT and MEK/ERK
activation is RAGE-dependent
5.2.2.5. S100P stimulates cell migration through AKT
and ERK 1/2 signalling pathway via the RAGE Receptor
68
73
75
76
77
77
81
87
92
94
96
97
100
100
103
103
107
113
116
118
5.3. Discussion
General Discussion
Appendix
References
122
124
129
146
Abstract
 
S100P is a member of the S100 family of small regulatory calcium-binding
proteins, which has been shownto play a role in the metastatic phase of cancer.
Intracellular overexpression of S100P under physiological conditions has been
correlated to metastasis and poor overall survival in breast cancer patients. The
mechanism of the Metastasis-Inducing Calcium-binding protein, S100P in metastasis
has notyet been fully elucidated.
Investigation of the role of metastatic S100P was divided into three parts,
investigating the effects of intracellular S100P oncell activity such as cell motility, the
expressions of other genes, and the effect of extracellular S100P on intracellular
signalling processes. Several analyses such as motility assays, gene expression using
microarrays, quantitative real-time PCR and SiRNA, changesin intracellular signalling
induced by addition of extracellular S100P have been performed. These experiments
werecarried out using an expression system developed in our laboratory consisting of
a human S100P cDNAinserted in a tetracycline-inducible vector transfected into non-
metastatic benign rat mammary tumour-derived cells (Rama 37), and human cervical
carcinomacells (HeLa).
Results observed after microarray hybridisation showed 5 upregulated genes
and 3 downregulated genes, after intracellular overexpression of S100P in rat
mammary tumourcells. Further analysis on upregulated gene knock-down using
SiRNA on oneselected up-regulated gene, the microtubule associated serine/threonine
’ kinase 1 (Mastl) helped defining S100P’s role on gene expression. Extracellular
addition of S100P has been shown to increase cell motility suggesting alternativecell
motility stimulation via a cell surface receptor. Extracellular S100P has been shown to
activate intracellular phosphorylation of a member of Serine/Threonine-specific
protein kinase family: Akt and Extracellular signal-Regulated Kinases: Erk 1/2 through
the Receptor for Advanced Glycosylation End-Product (RAGE).
Results enabled the Metastasis-Inducing Calcium-binding protein mechanisms
to becomeclearer so that S100P could represent a potential target for novel diagnostic
and therapeutic applications.
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1.1. S100 protein family
1.1.1. History
S100 proteins are small, acidic proteins (9-14 kDa) found exclusively in
vertebrates (Schafer and Heizmann, 1996). The first member was identified in 1965 by
Moore whoidentified a subcellular fraction from bovine brain “S100” named because
the constituents were soluble in 100% saturated ammonium sulphate at neutral pH
(Moore, 1965). With at least 25 members found to date in humans, the S100 proteins
constitute the largest subfamily of the EF-hand proteins (Table 1.1). Of these, 21 family
members (S100A1-S100A18,trichohylin, filaggrin and repetin) have genes clustered at
chromosomelocus 1q21, while other S100 proteins are found at chromosomeloci 4p16
(SLOOP), 5q14 (S100Z), 21q22 (S100B) and Xp22 (S100G).
1.1.2. Structure
S100 proteins show 25-65% identity to one another at the amino acid sequence
level and contain two distinct helix-loop-helix calcium-binding motifs known as EF-
hand, flanked by conserved hydrophobic residues and separated by a linker region.
The sequencesof the linker region and the C-terminal extension are the most variable
parts of the S100 protein sequences from one S100 protein to another (Schafer and
Heizmann, 1996). All S100 proteins, with the exception of S100G (calbindin D9k), are
organised as tight symmetric, antiparallel homodimers or heterodimers, with the non-
covalent interface between the two monomers being formed mostly by hydrophobic
amino acid residues (Heizmann etal., 2002). Each monomeris composedofa classic
EF-hand near the C terminus, commontoall EF-hand proteins, and a pseudo EF-hand,
near the N-terminus that has been found exclusively in S100 and S100-like proteins
(Donato, 2001; Santamaria-Kisielet al., 2006; Zhou etal., 2006) (Figure 1.1).
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Approved gene Symbol Gene
(gene name) eyene location
S100A1 S100aa 1q21
S100A2 CaN19, S100L 1q21
S100A3 S100E 1q21
CAPL, p9Ka, 42A, pL98, mts1, metastasin,
S100A4 calvasculin, 18A2, murine placental calcium 1q21
protein, fibroblast-specific protein (fsp)
S100A5 S100D 1q21
S100A6 CACY, 2A9, PRA, CaBP 5B10, calcyclin, Siah-1- 1q21
interacting protein (SIP)
S100A7 (isoform a-c) psoriasin, PSOR1, BDA111, CAAF2 1q21
S100A7A S100A15, S100A7L1, NICE-2, S100A7f 1q21
S100A7L2 (S100A7-like2) S100A7b 1q21
S100A7L3 (S100A7-like3) S100A7P1 (S100A7-pseudogene2), S100A7d 1q21
S100A7L4 (S100A7-like4) S100A7P2, S100A7e 1q21
MRP-8, p9, calgranulin A (CAGA); CP-10
_ (murine), L1 light chain, CGLA a
MRP-14, p14, calgranulin B(CAGB), L1 heavySLOOA9 chain, BEE22, CGLB iget
CAL12, CLP11, P11, p10, 42C, calpactin light chain,
S100A10 annexinII ligand, calpactin I, light polypeptide, 1q21
ANX2LG, CAL1L, GP11
calgrizzin, S100C, MLN70
S100A11 (metastatic lymph node gene 70 protein), protein 1q21
$100-C
CaBP in Amniotic fluid-1 (CAFF1), P6, calgranulin
C (CAGC), calgranulin-related protein (CGRP),
S100A12 MRP-6, CaBPcornea-associated antigen (COAg); 1q21
extracellular newly identified RAGE-binding
protein (EN-RAGE), neutrophil S100 protein
S100A13 1q21
S100A14 S100A11P, S100A11 pseudo gene, BCMP84, 1q21
S100A15,S114; breast cancer membraneprotein 84
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Approved gene Symbol Gene
(gene name) neyns location
aging-associated gene 13 protein (AAG13),S100A16 1q21DT1P1A7, MGC17528, S100F
trichohyalin-like 1 protein, (CHHL1 ), THHL1;S100A17 1q21
S100A17; basalin; TCHHL1
 
S100B S100B 21q22
S100P 4p16
S100Z 5q14
Repetin 1q21
S100G Calbindin 3 (CALB3); calbindin D9K (CABP9K) Xp22
Table 1.1 S100 Family nomenclature and synonyms
The EF hand is a helix-loop-helix structural domain, first described by
Kretsinger and Nockolds (Kretsinger and Nockolds, 1973) found in a large family of
calcium-binding proteins consisting of an alpha-helix (E), loop and a second alpha-
helix (F). The majority of S100 proteins have two distinct EF-hands that bind Ca?* ions
with different affinities (Baudier et al., 1984; Strynadka and James, 1989). The pseudo
EF-hand found between the helix 1 and helix 2 in the N-terminal region has a lesser
affinity than the canonical EF-hand found in the C-terminal region between helix 3 and
helix 4. Most S100 proteins undergo a large conformational change upon Ca** binding
to the canonical EF-hand and this exposes a large hydrophobic pocket which wasfirst
seen in early studies of S100A and S100B (Baudier and Gerard, 1983). Calcium binding
to the pseudo EF-hand does not cause any conformational changesin helices 1 and 2.
During the significant conformational change, Ca** binds the canonical EF hand,
reorienting helix 3 from almost parallel with helix 4 in the apo form to almost
perpendicular (~90° reorientation). This changein helix 3 instead of helix 4 is a unique
characteristic of S100 proteins compared to other EF-hand proteins. S100B has an
almost 90° reorientation of helix 3, while other S100 proteins such as S100A4 havea less
drastic effect (~60°) and S100P experiences no change at all (Lee et al., 2004;
Malashkevichet al., 2008; Zhanget al., 2003).
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1.1.3. Functions
S100 proteins are expressed in a tissue andcell-specific fashion (Donato, 2001),
mostly detected in the cytoplasm and in somecasesin the nucleus of normalcells. For
example, S100A1 and S100A2 are found in the cytoplasm and nucleus, respectively of
smooth-muscle cells (Mandinova et al., 1998), whereas S100P is located in the
cytoplasm of placental tissue (Becker et al., 1992; Emotoet al., 1992). It is thought that
S100 proteins predominantly serve as a calcium trigger or sensor proteins that, upon
calcium dependentactivation, regulate the function and/or subcellular distribution of
certain target proteins and peptides (Donato, 2003; Ravasi et al., 2004; Santamaria-
Kisiel et al., 2006).
L1 L2
EF-hand EF-hand
Non-Cannonical Cannonical
Hinge VariableRegion Domain
Cc
Helix | Helix II Helix Ill Helix IV
Figure 1.1 Schematic representation of the secondary structure of a S100 protein.
Each Ca?*-binding loop (L1 and L2, in the N- and the C-terminalhalf, respectively) is flanked by
a-helices (helices I and II, and helices III and IV for L1 and L2, respectively). A linker region (hinge
region) connects helix I-III. Helix IV is followed by a C-terminal extension. The hinge region and the C-
terminal variable domain extension display the least amount of sequence similarity between family
members (Donato, 1999; Kligman and Hilt, 1988; Schafer and Heizmann, 1996).
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Whentheyare present extracellularly, some members of the S100 protein family
can act as leukocyte chemoattractants, macrophageactivators and modulators ofcell
proliferation in cultured cells (Cornishet al., 1996; Devery etal., 1994; Hiratsukaetal.,
2006; Lau et al., 1995; Yen et al., 1997). Extracellular functions have been mainly
described via a multiligand cell surface receptor for advanced glycation end-products
(RAGE), a member of the immunoglobulin superfamily of cell surface molecules,
which is expressed on leukocytes and endothelial cells and has been to shown to be a
receptor for S100A1, S100B (Huttunenetal., 2000), S100A8, S100A9 (Ehlermann etal.,
2006), S100A12 (Hofmann et al., 1999), and S100P (Arumugam etal., 2004), and
activating downstream signalling pathways. Intracellular functions include regulation
of protein phosphorylation and enzymeactivity, calcium homeostasis, regulation of
cytoskeletal components (Fanoet al., 1989; Kriajevskaet al., 1998; Sorci et al., 2000) and
regulation of transcription factors (Baudier et al., 1995). A number of members of the
S100 family have also been shown to play a role in modulating proliferation, some,like
S100A1, have been shownto inhibit cell proliferation (Zimmer etal., 1998). Most of the
S100 family members have a role in modulating cytoskeletal dynamics, exhibiting
direct interaction with tubulins, intermediate filaments, actin, myosin and tropomyosin
(Davies et al., 1993; Santamaria-Kisiel et al., 2006). These processes have been
implicated in mediating metastasis (Davieset al., 1993; Donato, 2003; Kriajevska etal.,
1998) and are implicated in actin polymerisation and the subsequent formation of
membraneprotrusions that are required for chemotaxis. Remodelling of the actin
cytoskeleton is indeed important for motility and chemotaxis of cancer cells, which in
turn influence the metastatic capability of these cells. These functions could implicate
S100 proteins in a variety of pathologies and gradually their role in carcinogenesis is
beginning to be unravelled. It is clear that some 5100 proteins may act as tumour
promoters and others may act as tumour suppressors, and there is exquisite tissue
specificity in their actions (Salama etal., 2008).
1.1.4. S100s, Cancer and Metastasis
Cancer is a general term used to describe a group of more than two hundred
diseases sharing commoncharacteristics (Hanahan and Weinberg, 2000). Properties
known as the “Hallmark of Cancer” acquired by most human tumoursare:self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of
6
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apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion
and metastasis (Hanahan and Weinberg, 2000). Each of these physiological novel
capabilities acquired during tumour developmentrepresents the successful breaking of
an anti-cancer defence mechanism applied by cells and tissues. In most cases, tumours
are benign, meaning that they are not cancerous. They may cause health problems
depending on their size and location, but do not have the ability to infiltrate
surrounding tissue (invasion) or to spread to distant organs (metastasis), a synonym of
malignant cancer progression. The usual organ targets of cancercell metastasis are the
lung, brain, bone andliver, often leading to the cause of patient death (Cancer Research
UK), as very few patients with metastatic cancer are currently curable (IARC, 2010).
Cancer is a major worldwide health problem, seeing the total number of
diagnosed cases and deaths is increasing, with a projection of new estimated cases to
jump from 11.3 million in 2007 to 15.5 million in 2030 (Source World Health
Organisation), combined with a projected 45% increase in death from 2007 to 2030
(from 7.9 million to 11.5 million deaths) (IARC, 2010). The leading causeof this increase
is an increasing and ageing global population, but takes into consideration the
expected decline in death rates for some cancers in highly resourced countries.
The most frequent types of cancer worldwide (in order of the number of
global deaths) are:
e Among men: lung, stomach,liver, colorectal, oesophagus and prostate
e Among women:breast, lung, stomach, colorectal andcervical.
In females, breast cancer has the highest incidence rate in the world (1,400,000
cases) and in the UK (45,700 cases) (IARC, 2010). Breast cancer is the most common
female cancer in the UK. Breast Cancer patients’ prognosis dependsonseveral factors
e.g. human epidermal growth factor receptor (HER)-2 (Slamonet al., 1987) or the
transcription andtranslation factor Y-box binding protein-1 (YB-1) (Wuetal., 2006), but
the later the stage of the disease at diagnosis, the lower the survival rate. Women
diagnosed before the occurrence of metastasis have 5 year survival rates varying from
99% to 44% from early to late stage and grade andthe 5 year survival rates drop down
to 14% after apparition of distant metastasis (Cancer monthly, The Source for Cancer
Treatment Results).
Several studies to understand cancer and mechanisms of metastasis and
involved proteins have been performed, and the presence of some membersof the S100
protein family have been correlated with metastasis. S100A4, one of the most studied
7
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proteins of the S100 family, has been characterised as a metastasis-associated protein
(Davieset al., 1993). The association with a high metastatic capacity wasfirst described
for rodent tumour cell lines that had a high level of S100A4 protein and mRNA
expression (Ebralidze et al., 1989). Further research then reported that transfection of
rat (Davies et al., 1993), or human cells (Grigorian et al., 1996) with S100A4 cDNA,
whenis expressed as protein (Davieset al., 1993), can introduce a metastatic phenotype
in non-metastatic rat mammary tumour cells (Rama 37) (Davieset al., 1993; Grigorian
et al., 1996). When transfected cells overexpressing S100A4 were injected
subcutaneously, it resulted in tumour development with a significant reduction in the
latent period (~50%) and the appearance of metastases in the lungs and lymph nodes.
Cells overexpressing S100A4 exhibited increased invasive characteristics, such as
penetrating connective tissue and invading adjacent skeletal muscle (Davies et al.,
1993), whereas inhibition of S100A4 expression in metastatic cells can revert cells to a
less metastatic phenotype (Maelandsmoet al., 1996). S100A4 is not tumorigenic itself,
since it failed to develop tumours in transgenic mice overexpressing S100A4protein
(Ambartsumian et al., 1996; Davies et al., 1996), but acts as a metastasis inducer in a
given tumorigenic background.
The association between S100A4 expression and metastasis observed in animal
studies has led to a number of studies of S100A4 as a prognostic marker in human
cancers. A study, over a period of 14-20 years evaluated 349 invasive human breast
cancer specimens for expression of S100A4 and othervariables. This study showedthat
patients with carcinoma positively stained for S100A4 were highly correlated with
patients’ death (Platt-Higgins et al., 2000; Rudlandet al., 2000). In addition to breast
cancer, S100A4 has been shown to be a prognostic marker in a number of other human
cancers, including oesophageal-squamous cancers (Ninomiyaetal., 2001), non-small
cell lung cancers (Kimuraet al., 2000), primary gastric cancers (Yonemuraetal., 2000),
malignant melanomas (Andersenetal., 2004), prostate cancers (Saleem et al., 2005),
thyroid carcinomas (Zou et al., 2004), bladder cancers (Davies et al., 2002) and
pancreatic carcinomas(Rosty et al., 2002). Different studies have then been performed
to determine the mechanistic functions of S100A4 in several different facets of tumour
progression, including motility, invasion, angiogenesis and apoptosis. Motility and
invasion have been studied using several transfectedcell lines. These have shownthat
S100A4 stimulates cell motility (Davies et al., 1993; Jenkinson et al., 2004) via an
interaction with non-muscle myosin IIA (Kriajevska et al., 1994). Matrix
8
Chapter1 Introduction
 
Metalloproteinases (MMPs) have been also implicated with an essential role in cell
migration up-regulated by S100A4 (Schmidt-Hansenet al., 2004).
Other members of the S100 family such as S100B, S100A7, S100A8, S100A9 and
S100P, have also been studied and have been related to metastasis and poor patient
prognosis. S100B has been significantly associated with melanoma (Schultz et al., 1998),
increasing serum level of S100B are associated with tumour stage (Bonfreretal., 1998),
and there is a high expression in metastatic melanomas (Heizmann, 2004; Schultz etal.,
1998). The level of expression of S100B reflected patient prognosis (Hauschild etal.,
1999a; Hauschild et al., 1999b; Schultz et al., 1998), and S100B serum levels have been
correlated with patient survival, distinguishing three different risk groups depending
on S100B levels (< 0.3 pg/I1, 0.3-0.6 pg/1 and > 0.6 pg/1 in a 643 melanoma patients
cohort (von Schoultz et al., 1996). S100B is also implicated in the regulation of tumour-
suppressor p53 oligomerisation (Fernandez-Fernandez et al., 2005; van Dieck etal.,
2009). S100A7 is up-regulated in skin (Alowami etal., 2003), bladder (Celis et al., 1996),
and in breast cancers (Al-Haddad etal., 1999; Leygueet al., 1996; Moog-Lutz et al.,
1995). S100A7 has been associated with cell migration and invasion in tumour breast
cells (Krop et al., 2005). S100A7 nuclear expression has been significantly associated
with poor patient prognosis in a cohort of 100 head and neck squamouscell carcinoma
(HNSCC) patients over samples from patients with oral displastic lesions (Tripathi et
al., 2010). The heterodimer S100A8-A9 has also been implicated in metastatic process in
several types of cancers such as prostate (Hermani et al., 2006) or Lewis lung
carcinomas (LLC) (Hiratsuka et al., 2006), but most interestingly has been shown to
increase the motility of lung cancer cells by a p38 MAPK-mediated activation of
tumour cell pseudopodia (Hiratsuka et al., 2006).
A recent study has demonstrated that transfection of a vector expressing S100P
into a benign non-metastatic rat mammary cell line caused a threefold increase in local
muscle invasion and a significant induction of metastasis in up to 75% of tumour-
bearing animals (Wanget al., 2006). A study of S100P immunohistochemistry in 303
breast cancerpatients clearly indicated that the survival of patients with S100P-positive
carcinomaswas significantly worse by about seven fold than for those with carcinomas
negatively stained for S100P. Thereis also a significant correlation betweenintensity of
immunohistochemical staining of the carcinoma cells for S100P and decreased patient
survival (Wanget al., 2006).
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Figure 1.2 Human S100P protein sequence.
Human S100P protein Sequence (NP_005971, NCBI Pubmed). The S100P monomer structure
containsfour helices; namely, helix I (residues 3-18), helix II (residues 30-40), helix III (residues 53-61),
andhelix IV (residues 71-92). In S100P, the two calcium-binding loops contain two short, antiparallel B-
strandsformedby residues 27-28 and 68-69, respectively (Zhangetal., 2003).
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1.2 S100P
1.2.1. Structure
 
S100P is a 95-amino acid, 10.4 kDa member of the $100 family, first isolated in
1992 from human placenta (Becker et al., 1992; Emoto et al., 1992). S100P protein
structure has 2 distinct EF hand motifs separated with a hinge (L41-V54) region (Figure
1.2) and contains four helices; namely, helix 1 (residues 3-18), helix 2 (residues 30-40),
helix 3 (residues 53-61), and helix 4 (residues 71-92). The two calcium-binding loops
contain two short, anti-parallel B-strands formed by residues 27-28 and 68-69,
respectively (Figure 1.3 A). Ca?*-binding loops of the two EF-hands acquire a Ca**-
bound-like conformation by Hydrogen bonds between the two £-strands. S100P exists
in solution as a homodimer which is formed by hydrophobic interactions between
subunits along the N-terminal helix 1 and the C-terminal helix 4 of subunits through
anti-parallel packing (Figure 1.4 B). Two metal-binding sites are located in the C-
terminal and N-terminal loops of each monomer, with different calcium binding
affinities, a high affinity in the C-terminal loop and a lowaffinity at the N-terminal
loop (Gribenko and Makhatadze, 1998). These C and N-terminal sites can also bind
other divalent ions. The C-terminal site can bind Zn** (with relatively low affinity), and
the N-terminal site can bind Mg?*. In response to calcium binding, the C-terminal
domain undergoes refolding that exposes its hydrophobic region and thereby
facilitates interactions of S100 proteins with target molecules that mediate a spectrum
of extracellular and intracellular effects.
Biochemical properties and crystal structure of S100P show significant
similarities to other S100 proteins. S100P is structurally similar to S100B, which is
consistent with 44% identity of the amino acid sequence alignment, as well as S100A7
and calbindin, despite their low level of amino acid sequence identity (25% comparing
with S100A7 and nosignificant similarities comparing with calbindin) (Zhanget al.,
2003).
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Linker region’  
  
 
Linker region
Figure 1.3. 3-Dimensional structure of S100P monomer and dimer
(A) $100P monomer. Calcium ions are in blue. Helices 1, 2, 3 and 4 are shownin flesh, lilac, pale-
green and orange, respectively. Loops 1 and 2 are shown in pink and khaki. The linker region is in
sky-blue, part ofwhich is invisible and marked with a broken line.
(B) S$100P homodimer. Two monomers are shown in red and blue respectively. The blue spheres are
calcium ions. Amino acid residues 46-51 in thelinker region are invisible, and are indicated by a
broken-line. Regions ofcontact between the subunits are markedin yellow.
(Zhang etal., 2003).
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1.2.2. S100P in Cancer, Role and Function
There is considerable increasing evidence that S100P playsa role in cancer. The
gene for S100P has been found to be highly expressed in several forms of cancer,
including pancreatic (lacobuzio-Donahue et al., 2002), prostatic (Averboukh et al.,
1996), colon (Bertram etal., 1998), breast (Guerreiro Da Silva et al., 2000), oesophagus
(Satoet al., 2002), and lung cancers (Diederichs et al., 2004).
- Pancreatic cancer
Abnormal expression of S100P has been consistently detected in pancreatic
tumours. Overexpression was observed to be specific to pancreatic cancercells, as it
was not detected in samples of an inflammatory disease with similar peculiarities to
pancreatic tumours, chronic pancreatitis (Logsdon et al., 2003). The specificity for
cancer cells was confirmed in microdissected pancreatic cancer tissues and isolated
primary cultures of cancer and stromal cells (Ohuchida etal., 2006). S100P is one of the
most common genetic alterations in pancreatic cancer (Crnogorac-Jurcevic et al., 2003;
Denget al., 2008; Dowenet al., 2005; Iacobuzio-Donahueet al., 2002; Logsdonetal.,
2003; Missiaglia et al., 2004; Ohuchidaet al., 2006), and has been detected in 90% of
pancreatic tumours (Arumugam etal., 2005), suggesting that S100P is an important
factor in pancreatic cancer progression, since it has been observed to stimulate
proliferation, survival, motility, and invasiveness of these cells (Arumugam etal.,
2005). Specificity of S100P overexpression in cancer suggested its use as a histological
marker for the disease, and as it has also been proposed to be a marker of pre-
malignacy. S100P’s role in tumour progression has been supported by the detection of
S100P expressionin the early stages of preneoplastic epithelial neoplasms (PanIN) with
an expression level increase in invasive adenocarcinoma (Dowen et al., 2005).
Mechanisms responsible for the induction of S100P gene expression during
tumorigenesis are not fully understood.
S100P is secreted from pancreatic cell lines, and extracellular S100P was found
to act extracellularly through the RAGEreceptor and activate extracellular-signal-
regulated kinases 1 and 2 (Erk 1/2), members of the mitogen activated protein kinase
family (MAP Kinases), and NFxB signalling pathways in pancreatic cell lines, which
increasedcell proliferation, migration, survival and tumour growth (Arumugam etal.,
13
Chapter1 Introduction
 
2004; Arumugametal., 2005). These two pathwaysare constitutively active in most
pancreatic cancer cell lines (Wang et al., 1999). S100P was also found to be secreted
extracellularly and act as an autocrine loop involving S100P and RAGE. Thus
inhibition of the S100P RAGE interaction with cromolyn (disodium 1,3-bis [(2-
carboxylatochromon-5-yl)oxy]-2-hydroxy- propane), an anti-allergy compound
(Berman et al., 1975) that has previously been shown to bind specifically to other
members of the S100 protein family (S100A1, S100A12, S100A13) (Okadaetal., 2002;
Oyama et al., 1997; Shishibori et al., 1999), decreased S100P-mediated increases in
cancer cell growth, survival, and invasivenessin vitro. Moreoverthe effects of S100P on
cell signalling, cell proliferation, and cell survival were blocked by agents that
interfered with the RAGE receptor when extracellular S100P was added to the
fibroblastic cell line, NIH3T3 (Arumugam et al., 2004). Furthermore siRNA-based
knockdown of endogenous S100P mRNA, and thus silencing of endogenous S100P,
reduced tumourcell migration in vitro (Hamadaetal., 2009). Moreover reduction in
growth, survival and invasivenessin vitro led to a decrease in tumour volume by more
than 80% after 6 weeks, and reduced peritoneal dissemination and distant metastasis to
liver and lung. Comparedwith the control siRNA-bearingcells silencing also sensitised
cancercells to chemotherapeutic drugs, since overexpression of S100P affected the rate
of tumour growth in vivo and resistance of pancreatic cancer cells to 5-fluorouracil
chemotherapy (Arumugametal., 2005).
- Prostate cancer
Prostate glands homeostasis is androgen-dependent, and an unbalanced
decrease of androgen in normal prostate cells has been shown to promote normal cells
to a metastatic stage (Averboukh et al., 1996). Moreover S100P expression has been
shown to be regulated by androgen. Thus the expression of the S100P gene was
abolished after 30 h of hormone deprivation in LN-Cap-FGCprostate cancercells, but
wasthen restored within 50 h by the addition of synthetic androgen (Averboukh etal.,
1996). Furthermore expression of S100P mRNAhasbeen shown to be highly elevated
in prostate cancers usingtissue microarray, with the highest frequency of S100P protein
expression seen in metastatic prostate cancer (Moussesetal., 2002). Overexpression of
S100P has also been described in PC3 prostate cancercells. This promotescell growth
and proliferation in these humanprostate cancercells in vitro and in vivo and reduced
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apoptosis in vitro, suggesting a promoting and aggressive role for S100P in cancer.
These observations were confirmed by inhibition of cell growth after S100P gene
silencing (Basuetal., 2008).
- Colon cancer
S100P is highly expressed in nonpolypoid adenomas, which havedistinct
characteristics compared with ordinary polypoid adenomas and have been are
associated with an increased risk relative to polypoid adenomas of harboring high-
grade dysplasia and progressing to an invasive tumour(Kita et al., 2006; Richteretal.,
2003). S100P was shown to be expressedat greater levels in colon cancer than matched
normal tissue . S100P also stimulated colon cancer cell growth, migration and
exogenous S100P stimulated both ERK1/2 phosphorylation and NFxBactivity in vitro,
through the RAGEreceptors (Fuenteset al., 2007).
- Breast Cancer
Breast cancer is the most common cancer among women,andseveral tissue
analyses revealed an implication of S100P in breast cancer. It has also been shown that
S100P overexpression is associated with immortalisation of human breast epithelial
cells in vitro and early stages of breast cancer developmentin vivo (Guerreiro Da Silva
et al., 2000). Moreover S100P has been shown to be absent in normal breasttissue, but
can be detected in typical and atypical hyperplasias, and in in situ and invasive ductal
carcinoma, indicating a strong association between S100P overexpression and cancer
tumour progression (Guerreiro Da Silva et al., 2000). A positive correlation between
S100P and high risk breast premalignant lesions has suggested that S100P is involved
in the very early stages of breast carcinogenesis (Schoret al., 2006).
Previous studies in our laboratory have shown that S100P protein can induce
metastasis in a rat mammary cell system and its presence in cancercells is associated
with a poor outcomein breast cancer patients (Wanget al., 2006). Thus subcutaneous
injection of Rama 37 cells overexpressing S100P into the rat mammary fat pad region,
produced primary tumours with significantly higher muscle invasiveness compared to
cells transfected with vector alone. They also metastasised unlike the vector alone.
Metastases were observed in lungs, and axillary lymph nodes. Immunohistochemical
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staining confirmed intracellular staining for S100P was located in both nuclei and
cytoplasm of these resultant tumours/metastases. There was no staining for S100P in
the primary tumours of the rats injected with parental cells not expressing S100P
(Wangetal., 2006). Further immunocytochemical staining of human breast carcinomas
showed predominantly nuclear with some cytoplasmic staining for S100P. Unlike the
other S100 protein associated with metastasis, S100A4, which was found
predominantly in the cytoplasm (Rudlandetal., 2000), the overall survival for patients
with carcinomas stained positively for S100P was highly significantly worse than for
patients with carcinomas classified as negatively stained (Wanget al., 2006), These
results are comparable to those with two other predominantly cytoplasmically located
metastasis-inducing proteins, S100A4 (Rudlandet al., 2000) and osteopontin (Rudland
et al., 2002), with a strong decrease of overall patient survival with positively stained
tumours. Thus, both S100P and S100A4 showed the sameability to induce metastasis
in the same mammary cell system and to be associated with poor outcomes of breast
cancer patients. However it may be that the mechanism maybe different since S100P
was seen in the nucleus suggesting an additional transcriptional role for S100P
induction of metastasis.
- Other cancers
S100P has been also reported to be expressed in ovarian tumours and_ to be
associated with a worse patient prognosis (Surowiak et al., 2007). S100P is
overexpressed in gastric cancer (Liang et al., 2007; Shyu et al., 2003). Furthermore,
increased levels of S100P have been shown to be correlated with decreased survival in
patients with lung cancer(Beeret al., 2002; Diederichs et al., 2004).
1.2.3. Regulation of S100P expression
S100P transcription and protein tissue expression, observed by several
microarray and immunohistochemical studies, correlate with characteristic features of
the malignant phenotype. S100P expression has been shown to be controlled by
androgen and IL-6 via the androgen receptor (Averboukh et al., 1996; Hammacheret
al., 2005), since S100P mRNAis up-regulated in the presence of androgen and IL-6 in
prostate cancer cell lines. Moreover microarray analysis of breast cancercell lines
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showedthat overexpression of the proto-oncogene ERBB2 (HER2/neu) correlated with
S100P up-regulation (Mackayet al., 2003).
Furthermore upregulation of S100P has been associated with
hypomethylation of CpG pairsin the 5’UTR (untranslated region also known asleader
sequence) of the S100P mRNAin prostate cancers (Wang et al., 2007), in pancreatic
cancer (Sato et al., 2004) and in cervical carcinoma cells (Jakubickovaetal., 2005). CpG
dinucleotides are statistically underrepresented in the genome, but are found
concentrated at the expected frequencies in C + G rich regions, termed CpG islands,
that frequently coincide with promoter or gene-regulatory regions (Doerfler, 1983). In
the healthy genome, most CpG islands are unmethylated, and the associated genes
which are expressed (Bird, 2002) are mostly methylated (Baylin et al., 2000). Abnormal
global hypomethylation can lead to the activation of pro-metastatic genes. One such
example is, S100A4, expression of which has been shown to be increased in
hypomethylation conditions (Rosty et al., 2002). The S100P gene has been identified as
a target for hypomethylation during cancer progression, with 35 CpG sites and 6
predicted transcription factor binding sites identified in the S100P promoter region.
Thus S100P expression is up-regulated 12 fold in cell lines from prostate cancer
specimens over normal cell lines derived from radical prostatectomy specimens, with
S100P hypomethylated in 50% of the tumour-derivedcell lines (Wangetal., 2007)
Another study revealed that the bone morphogenetic protein 4 (BMP4), a
member of the transforming growth factor-beta (TGFB) superfamily (Wozneyetal.,
1988), induced transcription of S100P in a pancreatic duct epithelial cell line (Hamada
et al., 2009), although a regulatory element mediating this transactivation was not
identified.
1.2.4. Targets for interaction of S100P
The metastasis-inducing effects of S100P may be mediated by both
intracellular and extracellular protein functions. Thus S100P binding to the RAGE
receptor stimulated the extracellular signal-regulated kinases (ERK)-1/-2 and nuclear
transcription factor NFB. There are possible downstream mechanisms leading to cell
proliferation, migration, survival and tumour growth (Arumugam et al., 2004;
Arumugam etal., 2005; Fuentes et al., 2007). These effects can be blocked by agents,
which interfere with RAGE, suggesting that S100P mayact in an autocrine mannervia
17
Chapter1 Introduction
 
RAGE.S100P has been shown to interact intracellularly with, and partially activate the
protein, ezrin (Koltzscheret al., 2003), a membranecytoskeleton crosslinker protein of
the ezrin/radixin/moesin (ERM) family which has been implicated in metastasis
(Akisawaet al., 1999). Ezrin modulates the state of actin filaments via direct linkage
betweenactin filaments and the plasma membrane(Bretscheret al., 2002), although the
underlying mechanism is not fully understood. The S100P binding protein Riken
(S100PBPR) has been described to bind S100P (Dowenet al., 2005). S100P is also
capable of interacting with and to form heterodimers with other members of the S100
family, namely S100Z (Gribenko et al., 2001), S100A1(Wanget al., 2004) and S100A6
(Whiteman etal., 2007).
1.2.5. Subcellular localisation and tissue distribution of S100P
The S100P subcellular localisation has been described as nuclear/
supranuclear, cytoplasmic or membranous and differs depending on thecell/tissue
and experimental settings (Parkkila et al., 2008; Sato and Hitomi, 2002). This may
reflect the functional state of the protein and its actual interactions. S100P has been
shown totranslocate to the cell periphery upon binding to ezrin, as a dimer-specific
S100P ligand (Koltzscheret al., 2003), whereas binding to S100PBPR wasidentified to
occur in the cell nucleus (Dowen et al., 2005). These studies suggest that S100P
localisation is a dynamic process, requiring dimerisation, since the F15A mutated
S100P is unable to dimerise and is also incapable of translocation (Koltzscheretal.,
2003).
1.2.6 S100P possesses an unknown nuclear modeofaction for metastasis
Literature strongly supports the significant role of S100P during the
development and progression of different cancers (Bartling et al., 2007; Diederichset
al., 2004; Guerreiro Da Silva et al., 2000; Hammacheret al., 2005; Mousseset al., 2002;
Ohuchida et al., 2006; Schor et al., 2006), with a crucial vital role for metastasis
induction (Wang et al., 2006). S100P may have intracellular effects on cell function,
since S100P can interact with intracellular molecules including ezrin (Koltzscheretal.,
2003), and may be influenced by the complementof proteins expressed by a specific
cell. On the other hand the nuclear localisation of S100P raises the question of a
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potential role in gene expression (Figure 1.4), but any mechanistic links with metastasis
are unknown. Furthermore preliminary experiments by Dr G. Wang have shown that
adding large amount of S100P to the outside of Rama 37cells causes a redistribution of
the cytoskeleton (unpublished observation). However, the functions of this protein in
the nuclear, cytoplasmic, and extracellular compartments are not known. A better
understanding of the molecular and cellular events triggered by S100P and this
functional analyses could potentially contribute to the developmentof novel diagnostic
and therapeutic strategies for this metastasis-inducing protein.
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Figure 1.4 Diagrammatic illustration of the occurrence of S100P in a tumour cell
S100P protein is expressed in an inactive “apo” state and triggered by calcium ions to form
active homodimers (Gribenko etal., 1998; Gribenkoet al., 2002; Lee et al., 2004). These can operate either
in an intracellular manner or as extracellular signalling molecules (Arumugam et al., 2004). In the
cytoplasm, binding to ezrin leads to activation of ezrin, which is molecule implicated in metastasis,
moreover binding to S100PBPRtranslocates S100P into the nucleus (Dowenetal., 2005; Koltzscher et
al., 2003). Secreted forms of S100P can also bind to the extracellular RAGE receptor andactivate Erk/
MAPKpathwayto influence gene expression (Arumugametal., 2004; Fuenteset al., 2007).
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1.3. Aim of Project
The primary aim ofthe project is to understand the mechanisms whereby S100P
induces metastasis in cancercells. The project is divided into three parts, investigating
the effects of 1) intracellular S100P oncell activity such ascell motility; 2) the effect of
intracellular S100P on the expressions of other genes; and 3) the effect of extracellular
S100P onintracellular signalling processes.
Firstly, the effects of increased intracellular S100P on cell motility were
analysed using an inducible system constructed in the rat mammary cell line Rama 37.
Secondly, changes in up-regulation and down-regulation of the expression of
genes after induction of S100P were analysed using microarrays.
Thirdly, changes in intracellular signalling induced by the addition of
extracellular S100P were analysed.
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2.1. MATERIALS
2.1.1. Chemicals and Biochemicals
Chemicals Suppliers
2-mercaptoethanol(thioethylene glycol) Sigma-Aldrich, USA
2-Propanol (Isopropanol) Sigma-Aldrich, UK
Acrylamide / Bis-Acrylamide (30% w/v) Sigma-Aldrich, UK
Acetic acid
Agarose
Ammonium persulphate (APS)
Chloroform
Dimethylsulfoxide (DMSO)
Ethanol
Formamide , deionized
Glycerine
Glycine
Glycerol
Goat IgG Purified Immunoglobulin
Hydrochloride acid (HCI)
Methanol
Milk powder
Propan-2-ol
Phenol
Power Sybr Green PCR Master Mix
Fisher Scientific, UK
Sigma-Aldrich, UK
Sigma-Aldrich, UK
VWR,France
Sigma-Aldrich, UK
VWR,France
Sigma-Aldrich, UK
VWR,France
AnalaR, UK
VWR,France
Sigma-Aldrich, UK
VWR,France
Fisher Scientific, UK
Marvel, UK
Fisher Scientific, UK
VWR,France
Applied Biosystems, UK
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Chemicals Suppliers
Protease Inhibitor Cocktail Sigma-Aldrich, UK
Sodium chloride (NaCl) VWR,France
Sodium dodecylsulfate (SDS) Fisher Scientific, UK
Sodium hydroxide (NaOH) VWER,France
SYBR Safe DNAgelstain Invitrogen, UK
TEMED Bio-Rad Laboratories, UK
Tris-Base Fisher Scientific, UK
Triton X-100 Sigma-Aldrich, UK
Trizol reagent Invitrogen,UK
Tween-20 Sigma-Aldrich, UK
2.1.2. Kits
Kit Supplier
M-MLVReverse Transcriptase Promega, UK
SuperSignal® MestTiceChemiluminescent PIERCE, USA
REASTAIN Quick-Diff Kit Staining REAGENA,Finland
Solutions
RNeasy Mini Kit Qiagen, UK
Quantitect® Reverse Transcription Qiagen , UK
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2.1.3. Other Materials
 
Name Supplier
3MM Paper Whatman ,UK
ABI PRISM™optical adhesive covers Applied Biosystems, UK
DNAmassstandard(1 kb DNA ladder) Invitrogen, UK
Falcon™ 50 mL conical tubes BDBiosciences, USA
Falcon™ 15 mLconical tubes BD Biosciences, USA
Immobilin™ -P- PVDF, pore size 0.45 um Millipore, USA
Microcentrifuge tubes, PCR,clear, 0.5 ml Eppendorf, UK
Microcentrifuge tubes, PCR,clear, 1.5 ml Eppendorf, UK
Microcentrifuge tubes, PCR,clear, 2.0 ml Eppendorf, UK
MicroAmpplates, optical 96-well reaction Applied Biosystems, UK
plate
Superscript random hexamerprimers Qiagen, UK
SeeBlue Plus2 Pre-Stained Standard Invitrogen, UK
Transwell Permeable Supports Corning, UK
2.1.4. Solutions
2.1.4.1. Solutions
Solutions Composition
Tris Buffered Saline (TBS) 50mMTris
150mM NaCl
pH 7.4
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Solutions Composition
Phosphate-Buffered Saline (PBS) 137 mM NaCl
2.7 mM KCl
8 mM NaoHPO,
1.5 mM KH»POsu, pH 7.4
10% Sodium Dodecyl Sulfate (SDS)
1x Tris Borate EDTA (TBE)
Coomassie Staining Solution
Coomassie Destaining Solution
10% (w/v) SDS
ddH20
89 mM Tris-Base
89 mM Boric Acid
2mM EDTA(pH 8)
0.25% (w/v) Coomassie bb G250
50% (v/v) Methanol
10% (v/v) Acetic Acid
50% (v/v) Methanol
10% (v/v) Acetic Acid
 
2.1.4.2. Medium and Antibiotics for Cell Culture
Medium and Antibiotics Composition
Routine Medium
Trypsin Solution
Freezing solution
1x DMEM (GIBCO)
50 ng/ml Insulin
50 ng/ml Hydrocortisone
5% (v/v) Foetal Calf Serum (FCS)
0.008%( v/v) Trypsin in Versene
140 mM NaCl
3 mM KCl
8 mM Na2HPO.
1.5 mM KH2PO,
0.7 mM EDTA
pH 7.2
20% (v/v) FCS20% (v/v) DMSODMEM
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2.1.4.3. Western Blot Solutions
Western Blot Solutions Composition
1 x Loading Buffer
1 x SDS-PAGE Running Buffer
10% polyacrylamide SDS-PAGE Resolving gel
15% polyacrylamide SDS-PAGEResolving gel
125 mM Tris-HCl (pH6.8)
4% (w/v) SDS
20% (v/v) glycerol
0.004% (w/v) bromophenolblue
10% (v/v) 2-mercaptoethanol
25 mMTris-Base
192 mM Glycine
0.1% (w/v) SDS
ddH20
1.9 ml dd-H20
1.7 ml 30% (w/v) acrylamide
1.3 m1 1.5M Tris (pH 8.8)
0.05 ml 10% (w/v) SDS
0.05 ml 10% (w/v) Ammonium
persulphate
2 pL TEMED
1.1 ml dd-H20
2.5 ml 30% (v/v) acrylamide
1.3 ml 1.5 M Tris (pH 8.8)
0.05 ml 10% (w/v) SDS
0.05 ml 10% (w/v) Ammonium
persulphate
2 wL TEMED
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Western Blot Solutions Composition
5% SDS-PAGEStacking gel
1 x Transfer Buffer
Western Washing Buffer
BSA Blocking Buffer
Milk Blocking Buffer
APS
Stripping Buffer
0.68 ml dd-H20
0.17 ml 30% (w/v) acrylamide
0.13 ml 1M Tris (pH 6.8)
0.01 ml 10% (w/v) SDS
0.01 ml 10% (w/v) Ammonium
persulphate
1 pL TEMED
25mM Tris-Base
192mM Glycine
20% (v/v) Methanol
ddH20
0.1 % (v/v) Tween in TBS
3% (w/v) BSA in TBS
5% (w/v) PowderMilk in Western
WashingBuffer
10% APS (w/v) in ddH20
200 mM Glycine, pH2.5
0.05% (v/v) Tween-20
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2.1.5. Primers
2.1.5.1. Primers for quantitative real-time PCR
- Rattus Norvegicus
: Product cePrimer Sense Sequence Gene Bank Sequence ie Efficiency
s Acc Num positions (%)(bp)
5’- AAGGGCTCATGACCACAGTC-3’ 586 - 605GAPDH 5_GGatccacccaTcatetrcr-3 NM_017008 700 - 681 i ue
5’- GATGCCGIGGATAAATTGCT -3’ 249 - 268S100P_ 5 ACTTGTGACAGGCAGACGTG-37 NM_005980 356 - 337 a a
5'- TTCTCTCCACAAGGGACACC-3’ 561 - 580Folhl ‘5’. CTTCATGACCCGTTCCAGTT-3" NM_057185 650 - 631 89 9%
5’- GAAGAGCGGACCACGTTAAG-3’
Mast 1 NM_181089 4499-4478 109 1035'- CACTGCGGGGTACATTICTIT -3’ - 4568 - 4547 :
5’- GITGACGTCAGAGGGATGGT-3’Myc 1249 - 1268Target] 5’- TGGGCAATCTTATTGGGAAG-3’  NM001106207 3441399 i
5'- ATCTTGGGCAAACTGGTGAA -3’ 416 - 435S100A7a_ sy acccTTTCCTTGCAGACTGA-3°  NM_001109471 517 _ 40g ” 10k
5’- TTCATTGAGCACATCCTICG-3’ 472-491Cend2-  GGTAGCACACAGAGCGATGA-3 NM_022267 548 - 567 ue =e
5’- CTCTGGTGCAACGAGAACAA-3’ 226 - 245Pttglip => CCTCAAAGTTCACCCAGCAT-3°  NM_001013238 344394 a ee
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Prim s S Gene Bank Sequence Product Effici
ers ense equence Acc Num positions size iciency
(bp)
5’- CAGCAAGAGCACAAGAGGAA:3’ 1131 - 1150GAPDH "5.TGTGAGGAGGGGAGATTCAG-3" NM_002046 4993 1904 92 100
5’- GATGCCGTGGATAAATIGCT -3’ —S100P_ 5’ ACTTGTGACAGGCAGACGTG -3’ NM_005980 3a." 335 107 103
5’-ATTGCAGAGGCTGTTGGTCT-3’ 734 - 753Folh1 5/<CTGCTATCTGGIGGTGCTGA-3’ _NM_001193473 gan _g 106 100
5’-CTTCGCTTCTGGTATCTGGC-3’ 2258-2277Cend2_ 5TGTGGAATGTTGTGATGGGA-3" NM_001759 9363 9349 103 99
5'<CCAGTCTTGGCCTTAAGCTG-3’ 1164 - 1183Akr7a2._ 5’-GAGCAAGGCAGGAAGCTAGA -3’ _NM_003689 1248 - 1229 84 101
5/- AATTTCTCGATGCCCTCCTT -3’ 159 - 178Mastl &_ GGTGAAGTGCTGGTCAGGAT -3, NM_014975 259 - 240 100 100
5’- ACCCATGTCATCCCAGAGAG-3’ 3073 - 3092S100A7a_ 5 CTGCCATAGCAAATCAGCAA-3' NM_176823 317 3159 105 9
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2.1.6. SIRNA Sequences
SequenceGene SiRNA Name Acc. No Sense Sequence(5’ — 3’) Position
MAST 5’-CGGUUCUAGCUCUUGAAUATT-3’ 1446-1466
MAST 1 Rn 11 NM_181089 5’-UAUUCAAGAGCUAGAACCGTT-3’ 1466 - 1446
MAS 5’-GCACAGCUUCUAAUAUCUATT-3’ 1853 - 1873
MAST 1 Rn 2 NM 5’-UAGAUAUUAGAAGCUGUGCGT-3’ 1873 - 1853
MAS 5‘-GCAUGUUUCGCCGCACCAATT-3’ 60 - 80
ih RLMASELS NMUeie? 5’-UUGGUGCGGCGAAACAUGCTG-3’ 80 - 60
5’-GCCUCACCACCAACUUAUATT-3’ 1578 - 1598
— Rn_MAST1_4 —NM_181089 5’-UAUAAGUUGGUGGUGAGGCTC-3’ 1598 - 1578
Negative CtrLAlStars1 n/a n/a n/a
BLOCK-IT
Alexa
FluorRed n/a n/a n/a n/a
Fluorescent
Oligo
 
All SiRNA Probes were purchased from Qiagen, UK
2.1.7. Antibodies
2.1.7.1. Antibodies used in Western blotting
Antibody Produced Dilution
 
AB to in Buffer Dilution Supplier
qo Akt Rabbit — 1:1000 Cell SignalingTechnology®
et abit 3%BSA/ 44999 Cell SignalingTechnology®
(Ser473)
1° MAST1 Goat mua! 1:500 Santa CruzBiotechnology,
31
Chapter 2 Materials and Methods
 AB Antibody Produced Dilution
 
 
to in Buffer Dilution Supplier
. . 3% BSA/ Cell Signaling Technology®° .1° CyclinD2 Rabbit TBST 1:1000 UK
Anti-
1° human Sheep onBM 1:1000 R&DSystems, UK
PSMA
o  Anti-goat : 3% BSA/ . . .Z IgG Rabbit TBST 1:15,000 Sigma- Aldrich, USA
Anti- °2° mouse Rabbit > POA/ —y.09000 Sigma- Aldrich, USATBSTIgG
> Anti-rabbit 5% Milk/ . . .2 IgG Goat TBST 1:10,000 Sigma- Aldrich, USA
Anti- 3
2 sheep Donkey oe BSS} 1:5000 R&DSystems, UKTBSTIgG
2.1.7.2. Immunostaining Antibodies
Produced Dilution Pe *AB Name in Buffer Dilution Supplier
9 BD Transduction1° Anti-S100P Mouse om BBA 1:1000TBST Laboratories, UK
” Anti- 3% BSA/ . :2 aes Donkey TBST 1:5000 LifeSpan, UK
2.1.7.3. Other
Same Supplier
DPX mountant Merck, UK
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2.1.8. Cell Culture
2.1.8.1. Cell lines
 
 
 
Name System
Rama37 Rattus Norvegicus
HeLa HomoSapiens
2.1.8.2. Vectors
Vector name Supplier
pcDNA3.1(+) pcDNA3.1 (-) Invitrogen, UK
T-REx System Invitrogen, UK
2.1.8.3. Transfection Reagents
Reagent Supplier
Hiperfect Transfection Reagent Qiagen, UK
2.1.8.4. Inhibitors
Inhibitor Supplier
LY 294002 Calbiochem®, UK
Wortmannin Calbiochem®, UK
PD 98059 Cell Signaling, UK
Anti-rat RAGE Antibody R&D Systems,UK
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2.1.9. Instruments
Instrument Supplier
7500 Fast Real Time PCR Systems Applied Biosystems, USA
Chemidoc Gel documentation system BioRad, UK
Gelelectrophoresis power supply BioRad, UK
Mastercycler PCR-Machine
Micro-centrifuge
NanoDrop ND-1000 Spectrophotometer
SDS-PAGEMini-Protean gel apparatus
Molecular Imager® Gel Doc™ XR
Eppendorf, UK
Eppendorf, UK
NanoDrop Technologies, San Diego, USA
Biorad Laboratories, UK
Biorad Laboratories, UK
 
2.1.10. Software for data handling
Software Supplier
Quantity three BioRad, USA
7500 Fast-Time PCR Systems Applied Biosystems, USA
Sigmaplot Systat Software, USA
Excel Microsoft, USA
GelEval Frogdance Software, UK
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2.1. METHODS
2.2.1.TISSUE CULTURE
2.2.1.1. Cell culture
2.2.1.1.a. Cell lines used
Thecell lines used during this project were the non-metastatic rat mammary
(Rama) 37 cell line obtained from a benign DMBA-induced tumour in a Ludwig
OLAstrain of Wistar-Furth rats (Dunnington etal., 1983), and a human cell line
derived from an epidermoid carcinomaof the cervix (HeLa), the latter consists of
highly stable immortalised cancer cells, isolated from a cancer of the cervix of
Henrietta Lacks who died of cancer in 1951 (Schereret al., 1953).
- Rama37 T-25 cells transfected with inducible system
The rat mammary (Rama) 37 expresses undetectable levels of S100P protein
by Western blotting or immunochemistry. An inducible Rama 37 system has been
developed in the laboratory (Dr G. Wang); the construct contains a human S100P
cDNAregulated by tetracycline regulatory elements consisting of a tetracycline-
regulated expression system for mammalian cells: the T-Rex™ System From
Invitrogen™, This tetracycline-regulated system uses regulatory elements from the
E. coli Tn10-encoded(Tet) resistance operon (Hillen and Berens, 1994; Hillen et al.,
1983). Tetracycline regulation in the T-Rex™ system is based on the binding of
tetracycline to the tet repressor and depression of the promoter controlling
expressionof the geneofinterest (Yao et al., 1998). The components of the T-REx(™)
system include (cf Appendix Figure A.1 and A.2):
- An inducible expression plasmid for expression of S100P underthe control
of the strong human cytomegalovirus immediate-early (CMV) promoter
and twotetracycline operator2 (tetOz) sites (pcDNA™4/TO)
- A regulatory plasmid, pcDNA6/TR®, which encodes the Tet repressor
(TetR) under the control of the human CMV promoter
- Tetracycline or doxycycline for inducing expression
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S100P mRNA and protein can be induced by adding doxycycline to the
medium. Inducible expression of S100P cDNA expression plasmid construct is
underthe control of this antibiotic.
- Rama37cells transfected with pcDNA3 (Invitrogen®)
Rama 37 cells were transfected with a pcDNA3vector (5427bp) inserted with
S100P full length cDNA.This vector contain the following elements (cf Appendix
Figure A.3):
- Human cytomegalovirus immediate-early (CMV) promoter
- Multiple cloning sites in the forward (+) and reverse (-) orientations to
facilitate cloning
- Neomycin resistance genefor selection of stable cell lines
- Episomal replication in cell lines that are latently infected with SV40 or that
express the SV40 large T antigen
Rama 37cells transfected with empty vector were used as negative controls.
- HeLacells transfected with an inducible system
HeLacells were transfected with the T-Rex ™ System previously used with
Rama37cells (Dr Wang).
2.2.1.1.b. Routine culture
Rat mammary epithelial cell lines (Rama 37) and human HeLacells lines
(HeLa) were routinely cultured in Routine Medium. Cells were cultured at 37°C ina
humidified atmosphere containing 10% (v/v) carbon dioxide and 90%(v/v)air.
2.2.1.1.c. Routine passagingofcells
All cells were grown to approximately 80% confluence on 10 cm diameter
tissue culture dishes in Routine Medium. Medium wasaspirated off, dishes were
washed three times with 10 ml of PBS, 1 ml of trypsin solution was added and
swirled over the surface of the cells. Dishes were incubated at 37°C for 2-5 min to
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release the cells from the dish, and whenthe cells were detached 5 ml of medium
was addedto the plate and gently aspirated to disperse the cells. Cells suspension
from one dish was then aliquotedto five new dishes containing medium (split ratio
1: 5) (Warburtonet al., 1982a).
2.2.1.1.d. Freezing cells
Cells were conserved by cryopreservation. Cells were grown to
approximately 80% confluence in a 10 cm diameterdish, detached from thedish as
previously described, counted in a Z1™ Series COULTER COUNTER® Cell and
Particle Counter, and pelleted by centrifugation at 1500g. Cells were resuspendedin
Freezing Mediumto final density of 2 x 10° cells/mL, aliquoted into cryotubes and
then placed on dry ice for one h before transfer to a -80°C freezer, then to a -140°C
freezer for long term storage (McLellan and Day, 1995).
2.2.1.1.e. Thawingcells
Cryotubespreviously stored in a freezer were thawedin a water bath at 37°C
and the contents were immediately transferred to a Sterilin tube containing 20 mL
Routine Medium supplemented with a further 10% FCS and centrifuged at 1500g in
a bench-top centrifuge. The supernatant was removedbyaspiration and the pellet
resuspended in a suitable volume of Routine Medium supplemented with 15% (v/
v) FCS, following which, cells were plated out. Medium was then changed to
regular Routine Medium after 24 h (Freshney, 2005).
2.2.1.1.f. Counting cells
Cells were detached as described previously and counted using the Z1™
Series COULTER COUNTER®Cell and Particle Counter. Trypsinised cells were
resuspended in Routine Medium and 1 mLofthe cell suspension was addedto 19
mL of Isoton for counting. The numberof cells measured by the Coulter counter is
calculated in a volume of 500uL from the 20mL sample, so to calculate the
concentration of the 20 mL total volume, the numberofcells given by the Coulter
counter was then multiplied by 40 to determine the concentrationof cell/mL.
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2.2.1.1.g. Treatmentof cells
- Cell treatment with doxycycline
Prior to induction of S100P in cells transfected with the inducible system,
cells were washed three times with PBS, then 10 mL of Routine Medium containing
67.5 nM of doxycycline was addedto the cells. Cells were then cultured in normal
routine conditions.
- Cell treatment with inhibitors.
Inhibitors used for cell signalling analysis were: Wortmannin (Brian et al.,
1957; Hazeki et al., 1996), LY294002 (Vlahoset al., 1994), PD 098059 (Dudleyet al.,
1995) and Anti-RAGEinhibitors. Cells were washed three times with PBS and
pretreated with inhibitor for 30 min priorto starting experiments.
2.2.1.2. Cell migration
- Migration in a Boyden chamberassay
Cell migration assays were performed using the Boyden chamber assay,
based on a chamber of two medium-filled compartments separated by a
microporous membrane (Figure 2.1). Cells were placed in the upper compartment
and were allowed to migrate through the pores of the membrane into the lower
compartment (Boyden, 1962). The migratory ability of the cells were measured in a
Boyden chamberby passage througha filter membrane of 0.33 cm? growth surface
area containing 8 um pores in 24-well polystyrene tissue culture-treated sterile
plates (Transwell® Permeable supports, Corning Inc, NY, USA).
Chemotactic-induced migration in response to a FCS concentration gradient
was measured by adding 400uL of Routine Medium containing 10% (v/v) FCS to
the lower compartment and 8x104 cells in 200uL of Routine Medium, but with 2%
(v/v) FCS were addedto the upper compartment of the Boyden chamber. After the
cells had been incubated for 24 h, the upper side of the filter was wiped with a
cotton swab several times to removecells remaining on the upper surface and to
make sure that all cells on that side of the membrane had been removed, and the
cells on the lower sideof thefilter were fixed and stained using the Reastain Quick-
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Diff kit (Reagena, Finland), according to the manufacturer’s instructions.
Membranes were detached from the Transwell® insert and put between a
microscope glass slide and coverslip with a drop of PBS. Positively stained cells
which went through the membrane were scored looking through an optical
microscope (Magnification x 50). Each experiment, which consisted of triplicate
wells for each sample, were performedthree times.
 
 
 
 
 
  
 
Upper compartment > Transwell Insert
Lower compartment ——_}-—> Microporous Membrane
7
Cells GBt)Culture Media 5-
=
24h
Migratingcells
Motile cells
v
Cotton bud —————> —\!—___
Membrane with
LY Motile cells
Microscopeslide >
(+) (2°) Motile cells  
Figure 2.1 Experimental set up for cell migration in the lower compartment of the a
Boyden chamber
Cells were added to the upper compartmentof the Boyden chamber, and were incubated for
24 h under the experimental condition. Membranes were detached from the Transwell® insert, the
upper side of the membrane was gently wiped with a cotton bud, and put between a microscope glass
slide and coverslip with a drop of PBS. Positively stained cells which went through the membrane
were scored looking through an optical microscope.
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2.2.1.3. Characterisation of cell adhesion and proliferation
2.2.1.3.a. Cell adhesion assay
Cells were trypsinised, counted as described previously (Chapter 2: 2.1.1.f.)
and resuspended at 4x10° cells/mL in 5 mL. 1 mLofthe cell suspension was added
to each well of a 24-well plate and at time periodsof 0.5, 1, 1.5, 2, 2.5, 3 h, three wells
of cells were washed three times with PBS to remove anycells in suspension. Cells
adhering to the well were trypsinised and counted using a Coulter counter. Each
experimentconsisting of triplicate wells, were performed three times.
2.2.1.4 Analysis of cell lines
2.2.1.4.a. Immunohistochemicalstaining
Cultured cells were washed three times with PBS, trypsined, aliquoted in 1.5
mL Eppendorf tubes and spun down at 800 g. Cell pellets were then treated with
three changes of absolute ethanol, each for 2 h at room temperature, followed by
one washwith ethanol: 1 , 1 , 1 -trichloroethane (1:1 v/v) for 2 h and onefinal wash
with 1 , 1, 1-trichloroethane for 2 h. Cells were then incubated with four changesof
paraffin wax at 60 °C for 2 h, the last incubation being in a vacuum incubator, and
finally embedded in fresh wax, and dried overnightat 4 °C. Sections were dewaxed
by passage through three changes of xylene for 5 min each, three changes of
absolute ethanol for 5 min each, and rehydrated by immersion in water for 5 min.
Histological sections of cell pellets, cut at 4 ym, were transferred to 3-
aminopropyletriethoxysilane (APES) coated slides (Maddox and Jenkins, 1987) and
equilibrated with PBS (Ca?*, Mg”* free, PBS) (Warburtonetal., 1982b).
Indirect immunocytochemical staining was carried out using an enhanced
HRP labelled polymer system (DAKO EnVision + System, peroxidase (DAB) (Dako
Ltd, Ely, UK). Endogenous peroxidase activity was blocked using blocking agent
supplied with the Envision Kit before slides were incubated with 1% (w/v) BSA /
PBS for 30 min at room temperature. Monoclonal anti-S100P (BD Biosciences,
Cowley, Oxford) was then used at a dilution of 1:50 in 1% (w/v) BSA/PBSfor
approximately 2 h at room temperature in a moist chamber. Indirect
immunohistochemical staining was then carried out using the reagents prepared
according to the manufacturer's instructions. The sections were then washed in
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running tap water before being counterstained in Mayers’ haemalum. They were
then dehydrated through graded ethanol and xylene and were mounted in DPX
mountant (Heraset al., 1995).
2.2.1.4.b. Immunofluorescence
S100P was detected in cells by immunofluorescence as previously described
(Rudlandet al., 1989; Wanget al., 2000). Cells were grown to confluence and plated
at 50% confluence in an eight-well chamberedslides (Lab-Tek®) until approximately
60% confluence was reached. Cells were washed three times with PBS and once
with methanol, prior to fixing with methanol for 15 min at -20°C. The cells were
washed one more time with PBS and incubated for approximately 1 h with an
appropriate dilution of primary antibody diluted in 0.5% (w/v) BSA. Theslides
were then washed three times in PBS, for 3 min each, and incubated with the
relevant fluorescein isothiocyanate (FITC) conjugated secondary antibody at an
appropriate dilution for 1 h. The slides were washed with PBS as before, and
mounted using non-fluorescing aqueous mountant (Hydromount) (Johnsonetal.,
1982).
2.2.2. PROTEIN BLOTTING TECHNIQUES
2.2.2.1. Protein extraction
For Western blotting, total cellular protein wasisolated from cell lines. Cells
were grown to 70%-80% confluency in a 10 cm Petri dish, washed three times with
PBS buffer, scraped and collected with 100pL of 2x loading buffer (0.125M Tris-HCl
pH 6.8, 4% SDS (w/v), 20% glycerol, 0.004% bromophenolblue) in 1.5 mL tubes on
ice. Samples were sonicated on ice with 20 discontinuouspulses of 50% duty cycle
setting at an output control setting of 2, on an ultrasonic generator (type 7533A,
DAWE®, England, UK). Cell lysate was centrifuged for 10 min at 10,000g. Samples
of protein from cell lines in gel loading buffer were heated to 98°C for 10 min,
cooled on ice for 1 min, and were then separated by electrophoresis on
polyacrylamide-SDS gels.
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2.2.2.2. Denaturing polyacrylamide gel electrophoresis
(SDS-PAGE)
Protein samples in loading buffer were run for 1 h until the dye reached the
bottom of the resolving gel for Tris-Glycine SDS PAGE electrophoresis gels.
Polypeptides from different cell lines were analysed on different percentage
polyacrylamide resolving gels depending on thesize of protein to be detected, using
4% (w/v) acrylamidestacking gels in the Bio-Rad miniprotein system with 0.75 or 1
mm spacers, as described previously (Sambrook and Russell, 2001).
2.2.2.3. Coomassie blue staining of separated polypeptides after
SDS-PAGE
Proteins were visualised after SDS-PAGE by submerging the gel in
Coomassie blue-staining solution (50% (v/v) methanol, 10% (v/v) acetic acid, 0.25%
(w/v) Coomassie blue) at room temperature for at least 3 h with gentle agitation.
The gel was then destained by incubation in several changes of destaining solution
(10% (v/v) methanol, 5% (v/v) acetic acid) for up to 15 h (Sambrook and Russell,
2001).
2.2.2.4. Western blotting
Blotting of proteins onto an immobilon-P polyvinyldifluoride (PVDF)
membrane(Millipore, Bedford, USA) pre-soaked in methanol and rinsed in water,
wascarried out using a Bio-Rad semi-dry transfer apparatus for 1 h at 150 mA ina
blotting buffer (20 mM Tris-base, 150 mM glycine, 20% ethanol, 0.1% SDS) (Burnette,
1981).
The PVDF membranewasblocked for 1 h at room temperature with defatted
milk in Blocking Buffer, washed twice for 5 min with Washing Buffer and incubated
at 4°C overnight with primary antibody diluted in 5% (w/v) powdered milk in
Blocking Buffer. Subsequently, to remove unbound primary antibody, the membrane
was washed as before and incubated at room temperature with the secondary
antibody diluted in Blocking Buffer for 1 h on an orbital shaker.
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Proteins bound to horseradish peroxidase-conjugated secondary antibody
were detected by the Supersignal West Pico Chemiluminescent Substrate (Pierce
Biotechnology, Inc., Perbio Science, Framlington Northumberland, U.K.) according
to the manufacturer’s instructions. 1 mL of chemiluminescent reagents A and B were
combined and placed on the blotted dry membrane for 8 min before
autoradiography. The latter process involved exposures for 1 to 30 min on Fuji RX
film. Western blots were scanned, and protein amount quantified using GelEval
software.
2.2.2.5. S100P immunoprecipitation
Culture medium wastaken from treated or untreated cell culture plates of
growingcells and centrifuged at 1500 g in a bench-top centrifuge to remove dead
cells. The primary S100P antibody was added to the sample, placed in centrifuge
tubes, and left on a tube rotator at 4°C overnight. The following day protein A/G
agarose beads were washedthree times with 100 pL PBS before use, and were added
to the sample of culture medium and antibody andleft on a rotating wheel at 4°C
for 1 h to capture the immune complexes. Tubes were centrifuged for 30 secondsat
4°C, and the supernatant was carefully completely removed. The beads were
washed three times with 500 wL of cold Lysis Buffer. In order to minimise
background the supernatant was removed completely after each wash.After the last
wash 100 uL of two timeselectrophoresis Sample Buffer was added to the samples
which were boiled for 5 min, vortexed briefly, and boiled for 5 more min. Samples
were then subjected to the Western blotting protocol, as described in Section2.2.4.
2.2.3. MANIPULATION OF DNA
Agarosegelelectrophoresis
Agarose wasdissolved in 1x TBE buffer (describedin section I. 4 .a.) at the
required concentration (0.6 - 2%(w/v) by heating in a microwave oven. After
cooling for a few minutes at room temperature, SYBR Safe DNAStain was added to
agarose gels to a final concentration of 1 pL/mL andthe gel was set in 4 to 6 mm
deep gel casts in Perspex trays of varying sizes ( 4x 4 cm to 20x 20 cm). Onceset, the
gels were placed in appropriately sized tanks and submerged in 1 x TBE buffer. To
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increase the density of each DNA sample a 1: 2 volume of 2 x Loading Buffer was
added to each sample (described in Section 1.4.3.). Electrophoresis conditions
ranged from 60 - 120 V for 30-120 min (Sambrook and Russell, 2001).
2.2.4. MANIPULATION OF RNA
2.2.4.1. Isolation of RNA
Total RNA wasextracted from approximately 2 x 10° cells with TRIZOL®
Reagent (Invitrogen, U.K.) according to the manufacturer’s protocol. Cells were
washed three times with PBS and lysed directly in a 10 cm diameter culture dish by
adding 3 mL of TRizol Reagent, as described previously (Chomczynski and Sacchi,
1987). The cell lysate was passed several times through sterile pipette tip and
transferred into a 1.5 mL Eppendorf tube. Homogenised samples were incubated for
5 min at room temperature to permit the complete dissociation of nucleoprotein
complexes. 0.2 mL of chloroform was then added per 1 mL of TRizol Reagent and
tubes were shaken vigourously by hand for 15 s and incubated at room temperature
for 3 min. Samples were centrifuged at 10,000 g for 15 min at 4°C. Following
centrifugation, the aqueous phase containing RNA wastransferred to a fresh tube
and the RNA wasprecipitated by mixing with isopropylalcohol (0.5 mL per 1 mL of
TRizol Reagent) and standing at room temperature for 10 min before being
centrifuged at 10,000 g for 10 min at 4°C. The supernatant was removed from the
RNApellet which formed at the bottom of the tube, and the pellet was washed once
by adding 75% (v/v) ethanol. Samples were mixed by vortexing and centrifuged at
7,000 g for 5 min at 4°C. The RNApellet was briefly air-dried for 5 min and
dissolved in 50uL RNase-free water by passing the solution a few times through a
pipette tip, and incubated for 10 min at 58°C.
2.2.4.2. RNA clean-up
Total RNA waspurified using the RNeasy Total RNA Mini Kit (Qiagen,
UK) as described by the manufacturer to remove contaminating phenol. RNA
samples were adjusted to a volume of 100uL with RNase-free water, and 350yL of
Buffer RLT (Lysis buffer supplied by RNeasy Kit containing 25-50% (w/v)
guanidine thiocyanate) was added. Samples were mixed, 250yL ethanol (96-100%)
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was added to the diluted RNA and mixed well by pipetting. Samples were
transferred to an RNeasy Mini spin column, placed in a 2 mLcollection tube, and
centrifuged for 15 s at 13,500 g. The flow-through was discarded and 500uL of Buffer
RPE (Membrane bound RNAwashing buffer supplied by Qiagen) was addedto the
RNeasy spin column and centrifuged for 15 s at 9,000 g to wash the spin-column.
The flow-through was discarded and 500yL of Buffer RPE was added once more to
the RNeasy spin column and centrifuged for 2 min at 13,500 g to wash the spin
column. The RNeasy spin column wasthen placed in a new 1.5 mLcollection tube,
and 30uL of RNase-free water was added directly to the spin column, and the
mixture was centrifuged for 1 min at 9,000 x g to elute the RNA.
2.2.4.3. Determination of RNA concentration
The ratio of the optical densities from RNA samples measured at 260 and
280 nm in a spectrophotometer (Molecular Devices, SPECTRA® Max plus), was used
to evaluate nucleic acid purity, and total RNA concentrations were determined by
the absorbance at 260 nm. The A20/ A280 ratio of pure RNA is between 1.7 and 2
depending on base composition. At a wavelength of 260 nm, the extinction
coefficient for a single-stranded RNAis 38 (ug/mL)? cm". Thus, an optical density
(OD) of 1 corresponds to 38 pg/mL for single-stranded RNA (Alberts, 1994).
Concentrations and ratios were then confirmed by nanodrop spectrophotometer
sample analysis.
2.2.4.4. Microarray analysis of differential mRNA expression
RNAfrom untreated Rama 37 T-25 cells were compared to that from Rama
37 T-25 cells treated with 67.5 nM doxycycline for 72 h. Three separate experiments
were performed and total RNA was prepared from each sample, and used to
generate cRNA, which was labelled with biotin using the GeneChip® Two-Cycle
Target Labeling kit from Affymetrix. CRNAs were then hybridised to GeneChip Rat
Genomearrays (Affymetrix). A GeneChip Test 3 Array, containing a subset of 155
genes from several organisms including mammalian, plants and eubacteria, was run
to provide a convenient and accurate quality determination of labelled target RNA,
prior the main run on an Affymetrix GeneChip Rat Genome 2302.0 array. This array
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carried 31,024 probe sets representing 28,700 well-substantiated rat genes and was
purchased from Affymetrix (UK). The endogenous genes used for this chip were
GAPDH,beta-actin, and hexokinase 1. After a successful test, biotin-labelled cRNAs
were then hybridised on 6 Affymetrix GeneChip Rat Genome230 2.0 arrays with the
technical assistance of Dr Lucille Rainbow. After washing, the chips were scanned
and data were analysed.
- Microarray data analysis
Microarray data analysis was provided by Mr Brian Lane. The raw data
(CEL files) from the rat Genome arrays were representing 3 separate RNA
preparations of untreated and 3 separate RNA preparations of doxycycline-treated
Rama37 T-25 cell lines, the latter expressing intracellular S100P, were loaded into
the R statistical environment(v2.7.0) and processed with the appropriate (Gautier et
al., 2004) package of the BioConductor open-source library (Gentlemanet al., 2004).
Perfect match (PM) and Mis-Match (MM) data were generated and the MAS 5
algorithm was applied to these data to construct an ExpressionSet object which
contained single expression data values for each probe in each of the six arrays.
These linear-modeling results were subjected to an empirical Bayes moderation of
standard error using the limma package for BioConductor (v2.12.0), which allows
simultaneous analysis and comparison between many RNAtargets to determine
differential gene expression (Wettenhall and Smyth, 2004). The model of induced-
uninduced gene S100P expression differences generated first a standard linear
modelwith associated p-values indicating the significance of differential expression
(DE) for each gene and a Bayesian version of the model, as well as a false discovery
rate (FDR) adjustment for multiple testing (Smyth et al., 2003). The false discovery
rate (FDR) was proposed by Benjamini and Hochberg (1995) and is defined as the
expected proportion of false positive scores among the total numberofsignificant
scores. Algorithms based on FDR explore the elimination of false positives and
negatives independent of the number of samples being tested (Storey and
Tibshirani, 2003). The moderated p-value generated through FDR control sets a
threshold for an expected proportionof false positives in the selected genelist(i.e. a
p-value threshold of 0.05 should result in less than 5% of the geneson the selected
list being false positives). Output included the Bayesian equivalent of a p-value, an
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FDR adjusted p-value, the fold-change associated with the gene expression
differences and the log-odds of DE associated with each gene. Genes with evidence
of DE have log-odds >0, while those with no evidence of DE have log-odds<0
(Bolstadet al., 2003).
- Microarray validation
cDNAwas synthesised from the same set of RNA used for the microarrays
samples. Levels of individual mRNAs were measured with quantitative real-time
PCR. A standard curve was generated for each gene, composed of known serial
dilutions of cDNA,in order to establish the relationship between threshold cycle
(Ct) and mRNA concentration. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNAlevels were determined for all samples as a reference, and levels
of each mRNAwerecalculated as a ratio of the candidate gene/GAPDH values
(Freeman etal., 1999).
2.2.5. POLYMERASE CHAIN REACTION
2.2.5.1. Reverse transcription
Reverse transcription was performed according to the manufacturer’s
conditions (Promega). Two pg of total RNA isolated from cell lines and cleaned up
(as descibed in Section 2.4.2.) were placed in a sterile RNase-free microcentrifuge
tube, and mixed with 1pL of Random hexamer and 1pL of a mixed dNTP stock
(10mM each dATP, dGTP, dCTP, dTTP)in total volumeof 15yL. Tubes were heated
to 70°C for 5 min to melt secondary structure within the template, and thereafter
cooled immediately on ice for 1 min to prevent secondary structure from reforming.
Tubes were then centrifuged briefly to collect the solution at the bottom of the tube.
Samples were then mixed with 5uL 5X Reaction Buffer (250mM Tris-HCl (pH 8.3),
375mM KCI, 15mM MgCh, 50mM DTT), 50 units of Moloney murine leukemia virus
reverse transcriptase (M-MLV) RT, 25 units of recombinant RNasin ribonuclease
inhibitor and DEPC-treated nuclease-free water to a final volume 25p1. Contents of
tubes were mixed gently by flicking and were then incubated for 30 min at 42°C
(Sambrook and Russell, 2001).
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2.2.5.2. Polymerase chain reaction
PCR reactions (Sambrook and Russell, 2001) contained DNA template (100
ng), 2 pM forward primer, 2 1M reverse primer, 2 mM dNTP-mix, 1 pL of MgCh,
2.5 wL of NH4 Buffer (750 mM Tris-HCl pH 8.8, 200 mM (NH4)2SOu, 0.1 % (v/v)
Tween 20), 0.2 units of Tag DNA polymerase (Fermantas, UK) and PCR quality HzO
to a final volume of 25 wL. Cycling reactions were composed of primary
denaturation stage at 95°C for 5 min; 30 cycles of denaturation at 95°C for 30 sec, an
annealing step between 58-62°C (depending on primer annealing
temperatures) for 30 sec, an elongation at 72°C for 30 sec, and a final elongation
stage 72°C for 5 min. The samples were held at 4°C. A minimum of 5 pL of the PCR
reaction wasanalysed by agarose gel electrophoresis to verify the productsize.
2.2.5.3. Quantitative real-time Polymerase Chain Reaction
PCR primers for quantitative real-time PCR experiments were
designed with the Primer 3 (v. 0.4.0) design software available online: (http://
frodo.wi.mit.edu/primer3/). A Blast search was then performed on the NCBI
website (http://blast.ncbi.nlm.nih.gov/Blast/) to ensure the uniqueness of the
primer sequences (Altschul et al., 1990). The PCR primers were designed to cross
intron-exon boundaries (to allow detection of products of contaminating genomic
DNA)for each particular cDNA.
cDNA templates obtained from RNA samples was amplified by using
SYBR®Green PCR master mix (Applied Biosystems). The real-time PCRs were
performed in a 7500 Fast Real-Time PCR System (Applied Biosystems, USA) under
the following conditions: 95°C for 5 min, followed by 40 cycles at 95°C for 30 sec,
60°C for 30 sec, and 72°C for 30 sec.
Melting curve analyses were performed following the qPCR. The specificity
of the amplicons was confirmed by the presence of a single peak.
A standard curve, consisting of a dilution series of cDNA, was used
to determine the efficiency of the PCR reaction. Standard curves were generated
using a ten-fold serial dilution of a cDNA pool, and these enjoyed a linear
correlation coefficient (R2) of 0.991-0.999. Based on the slopes of these standard
curves, the estimated PCR amplification efficiencies were calculated from the slope
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of the standard curve using the following formula E = 10‘[(-1/R) -1 ]*100.
Efficiencies were ranged from 94% to 102% (cf Primerstable in section 2.1.5.1).
Calculation of efficiency and relative quantification was normalised to that
of the reference gene (GAPDH) and was carried out using the standard curve
method (Freeman et al., 1999). Individual samples were always measured in
triplicate to ensurereliability.
2.2.5.4. SIRNA
Small Interfering RNA (SiRNA) were purchased from Qiagen and sequences
are displayed in Table 2.1.6 SiRNA transfection was performed using HiPerfect
Reagent according to the Qiagen protocol. On the day of transfection, 6 x 10* cells
were seeded per well of a 24 well plate in 0.1 mL of Routine Medium.Cells were
incubated under normal growth conditions. 5nM SiRNA wasdiluted in 100 pL
culture medium without serum. After mixing by vortexing, 3 wL of HiPerFect
transfection reagent were added to the diluted SiRNA and vortexed for 10 s.
Samples were incubated for 5-10 min at room temperature to allow formation of
transfection complexes. Complexes were added, drop-wise onto the cells and the
plate was swirled gently to ensure uniform distribution of the transfection
complexes. Cells were then incubated with the transfection complexes under normal
growth conditions. After 3 h, 400 pL of Routine Medium was addedandthe cells
were incubated and gene silencing monitored.
To visualise SiRNA transfection efficiency, fluorescein-labelled, double-
stranded RNA duplex (BLOCK-IT™ Fluorescent Oligos, Invitrogen T™) were
transfected with SiRNA probes (sequences displayed in Section 1.6.). Fluorescence
wasvisualised after 12 h with a fluorescent microscopeto visualise the transfection
efficiency.
Knockdown of MAST1 using SiRNA probes was comparedto control probes,
AllStars Negative Control SiRNA,a validated negative control SiRNA from Qiagen.
This SIRNA has no homology to any known mammalian gene.It has been validated
using Affymetrix GeneChip arrays anda variety of cell-based assays and shown to
have minimal nonspecific effects on gene expression and phenotype (presented in
“data for AllStars Negative Control SIRNA”, Qiagen).
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2.2.5.5. Statistical analysis
All Statistical differences between groups were conducted using a
Student's t-test. Data presented for migration assays, cell staining, and gene
expression fold change are in the mean and standard deviation (S.D.) of triplicate
experiments performed three times. P value of less than 0.05 was considered a
statistically significant difference. Statistical calculation were performed using
Sigmaplot X and Excel software.
 Chapter 3
Identification of S100P as a Protein
Associated with Increased Cell
Migration
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3.1. Introduction
Tumour-cell invasion and metastasis is conventionally understood as the
process whereby individual cells detach from the primary cancer, enter lymphatic
vessels or the bloodstream andseed in distant organs (Gabriel, 2007). The ability to
migrate is a prerequisite for a cancercell to escape the primary tumour andenter the
circulation, and is highly dependent uponthe ability of tumourcells to undergo
directional migration (Bailly et al., 1998). The tumourcell respondsto stimuli in the
microenvironment that signals its detachment from the primary tumour mass,
invasion through the extracellular matrix and migration towards a blood vessel
(Wyckoff et al., 2000). It is a complex mechanism, and studies have associated some
of the S100 protein family members with metastasis and provided evidence
suggesting an influential role in metastasis promotion through a numberof different
processes (Salama etal., 2008) such as interactions with matrix metalloproteinases
(Bjornland et al., 1999), transcription factor regulation (Grigorian et al., 2001), and
migration (Takenagaet al., 1994a), as well as acting as chemoattractants (Devery et
al., 1994).
One member of the S100 family, the metastasis inducer S100A4, has been
shown to increase cell migration, and eight calcium-dependentintracellular targets
of S100A4 have been identified to date: tropomyosin (Takenagaetal., 1994b), heavy
chain of non muscle myosin IIA (Ford and Zain, 1995; Kriajevska et al., 1998;
Kriajevska etal., 1994), protein p37 (Dukhanina etal., 1997), S100A1 (Tarabykina et
al., 2000; Wanget al., 2000), p53 (Grigorian et al., 2001), methionine aminopeptidase
2 (Endoetal., 2002), the cell signalling associated liprin betal (Kriajevska et al.,
2002) and CCN3 a memberof a family of small cysteine rich secreted proteins (Li et
al., 2002).
Several observations support a role of S100P in invasive growth and
metastasis in cancers. During embryogenesis, S100P is expressed in trophoblasts of
the placenta and,in the adult, it is weakly present in normal tissues but expressed in
several cancer types (Parkkila et al., 2008), such as thoseof breast (Wang etal., 2006),
pancreas (Logsdonetal., 2003), or lung (Beeret al., 2002), and it has been associated
with poor patient prognosis in breast (Wanget al., 2006), and lung (Beeretal., 2002;
Diederichset al., 2004).
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An increase in S100P protein expression has been correlated with increasing
gradeof pancreatic intraepithelial lesions (Ohuchidaetal., 2006), and to increasecell
migration and invasiveness and to be associated with high levels of tumour growth
and metastasis (Arumugam etal., 2005). S100P was also associated with a hormone-
refractory and metastatic phenotypes in prostate cancers (Hammacheretal., 2005).
In breast cancer, increased level of S100P wasassociated with immortalisation and
tumour progression (Guerreiro Da Silva et al., 2000; Schor et al., 2006) and poor
patient prognosis (Wang et al., 2006). Moreover immunostaining of tumours
overexpressing S100P showedthe strongest expression in the cell nuclei (Parkkila et
al., 2008; Wangetal., 2006).
Cell migration is necessary for developmental morphogenesis, tissue repair
and regeneration, and has an important role in tumour metastasis. The regulation of
cell migration is important, and activation of metastasis-inducing elements such as
S100P stimulate the metastatic dissemination of tumour cells from their primary
location to lymph or blood vessels. Two different types of cell movement are
commonly described, namely random and directional movement. Random
movement occurs in the absence of a stimulus, and is characteristically multi-
directional with cells lacking directional persistence; this results in their moving
back and forth, in circles or remaining stationary with occasional protrusions and
retractions. In contrast, directional motility is usually initiated in response to a
signal, one common example is chemotaxis in which cells migrate towards a source
of growth factor or other chemical stimulus. Directional movementis
characteristically persistent, with cells becoming polarized and subsequently
migratory in straight paths toward the stimulus. Oneof the initial steps in cell
movementis the protrusion of the cell membrane, which is driven by localised actin
polymerisation (Rodriguezet al., 2003). Microtubules, one of the major components
of the cytoskeleton are also essential for cell migration andcell polarisation (Goode
et al., 2000).
To study the intracellular effects of S100P in tumour cells, inducible Rama 37
and HeLa cell systems have been developed in our laboratory (Dr G. Wang) to allow
the regulation of the intracellular production and level of S100P. The system
involved transfecting two expression plasmidsinto the target cells. One contains a
modified tetracycline repressor under human immediate-early (CMV) promoter
control (Lamartina et al., 2003) and the other, the S100P coding region cloned
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downstream ofa tetracycline regulatory element (Figure A.1) (Wanget al. submitted
for publication). The resulting rat mammary Rama 37 T-25 cell line and HeLa A-9
cell lines originate from clones transfected with the inducible system. Rama 37
pcDNA3-e (empty vector) and Rama 37 pcDNA3-S100P cell line clones
constitutively expressing S100P were used to examine the role of S100P in cellular
activities associated with the metastatic process (Figure A.2). Rama 37 cells were
chosenasthe in vitro model, because they express a very low amount of endogenous
S100P, which is undetectable by Western blotting and results were analysed and
correlated to the human system using HeLacells for similar reasons.
3.2. Results
3.2.1. Induction of S100P protein
When Rama T-25 cells were treated with doxycycline, production of
intracellular S100P was induced from the transfected inducible vectors. To confirm
the induction of S100P in stable transfected cell lines, in which S100P production
could be induced by doxycycline treatment, intracellular proteins were extracted
from doxycycline-treated and control untreated cells and subjected (as described in
Materials and methodsSection 2.2.1.1.g.) to Western blot analysis. Analysis showed
that the maximumlevel of S100P protein was obtained with 67.5 nM doxycycline for
Rama 37 T-25 and 112.5 nM doxycycline treatment for HeLa A-9 cells for 48 h
(Figure 3.1 and Figure 3.2).
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Figure 3.1 The effect of doxycycline concentration on the relative amountof intracellular
S100P in inducible Rama 37 T-25 cells
A. Western Blot analysis showing a representative experiment of intracellular expression of S100P
and f-actin in inducible Rama 37 T-25cells with concentrations ofdoxycycline shown.
B. Histogram showing the relative amountof intracellular S100P proteins compared to f-actin
proteins detected by Western Blot. Error bars represent the standard deviation calculated from
three separate blots.
C. Table showing the relative amountof intracellular S100P extracted from induced Rama 37
T-25 cells with concentration of doxycycline shown, and the standard deviation calculatedfrom
three separate blots.
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Figure 3.2 The effect of doxycycline concentration on the relative amountof intracellular
S100P in inducible HeLa A-9 cells
A. Western Blotanalysis showing a representative experimentofintracellular expression of S100P
and B-actin in inducible HeLa A-9cells with concentrations ofdoxycycline shown.
B. Histogram showing the relative amountof intracellular S100P proteins compared to B-actin
proteins detected by Western Blot. Error bars represent the standard deviation calculated from
three separateblots.
C. Table showing the relative amountof intracellular S100P extracted from induced Rama 37
T-25 cells with concentration of doxycycline shown, and the standard deviation calculatedfrom
three separateblots.
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When Rama 37 T-25 cells were treated with 67.5 nM of doxycycline, and
extracts of the cells subjected to Western blotting, the results showed a single band
on the gel at the expected molecular weight for S100P of 10.4 kDa within 24 h of
adding doxycycline (Figure 3.3 A). The same band wasvisible up to 96 h of
doxycycline treatment. Quantitation of 3 separate Western blotting experiments
showeda significant, 5-fold increasein the intracellular S100P/B-actin ratio up to 72
h (Figure 3.3 B), p < 0.0001 (Student'st-test, comparison between 72 h of doxycycline
treatment and untreatedcells).
Thereafter, between 72 and 96 h, there was no further significant increase
in the S100P/f-actin ratio, which remained at 5 fold (p = 0.835, Student's t-test
comparison between 72 h and 96 h of treatment). Conversely, when the Rama 37
T-25 cells were not treated with doxycycline, there was no significant increase in the
S100P/f-actin ratio between zero and 96 of induction (p = 0.694, Student's t-test).
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Figure 3.3 Stimulation of intracellular production of S100P protein in inducible Rama 37
T-25cells.
A. Western Blot analysis showing a representative time course of intracellular expression of
S100P and B-actin in inducible Rama 37 cells without treatment with 67.5 nM doxycycline.
B. Bar chart showing therelative amountofS100P proteins compared to B-actin proteins detected
by Western Blot
C. Table showing Student's t-test results between cells non-expressing S100P and cells
expressing S100P at the time shown. Data show mean + S.D from three independent
experiments (* p < 0.05).
58
Chapter3 Identification of S100P as a Protein Associated with Increased Cell Migration
 
Total RNA washarvested from the cells and relative expression levels of
S100P mRNA were determined by quantitative real-time PCR (as described in
Materials and methods Section 2.2.4). Quantitative real-time PCR experiments
confirmed the Western blot observations and revealed an increased level of S100P
mRNAexpression in Rama 37 T-25 cells treated with doxycycline for 72 h (Figure
3.4). Expression of S100P mRNAwasnormalised to the transcript of the reference
gene GAPDH, and was compared to RNA from non-expressing, S100P-untreated
Rama 37 T-25 cells (Figure 3.4 A). These quantitative real-time PCR experiments
indicated a 13-fold upregulation of S100P mRNA (Figure 3.4 A). This value is
consistent with the 10-fold increase of S100P protein in the inducible Rama 37 cells
uponinduction.
A constitutive Rama 37 pcDNA3-S100Pcells transfected with a constitutive
expression vector, pcDNA3, containing S100P cDNA were also analysed by
quantitative real-time PCR and Western blotting, then compared to Rama 37cells
transfected with an empty pcDNA3 vector (Rama 37 pcDNA3-e), to determine
whether the inducible system is inducing the mRNAandprotein to levels similar to
the constitutively-transfectedcells relative to non-expressing cells. Quantitative real-
time PCRanalysis of the constitutively-expressing rat cells revealed a significant 17-
fold upregulation of relative S100P mRNA(p = 0.002, Student's t-test) and Western
blotting revealed a significant 12-fold upregulation of S100P protein (p = 0.001,
Student's t-test) relative to empty vector control cells (Figure 3.4). No detectable
S100P protein bands were visible by Western blot in empty vector control cells (p =
0.0005, Student's t-test) (Figure 3.4 A-B). Quantitative real-time PCR analysis
indicated differences between the inducible system S100P protein mRNAexpression
and vector constitutively overexpressing S100P, with a stronger staining intensity in
cells constitutively expressing S100P. These observations were confirmed by western
Blotting (Figure 3.4)
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Figure 3.4 S100P mRNAandprotein expression in Rama37cells
A. Quantitative RT-PCR showing the levels of S100P in transfected Rama 37 cells. Expression
levels were measured from cell cultures isolated at 0 h and after cultivation in medium
containing doxycycline (67.5 nM) for 72 h. The qPCR result were first normalised to
housekeeping gene GAPDH.Finally, this normalised expression was compared to untreated
cells (for Rama 37 T-25) andcells transfected with empty pcDNA3vector for Rama 37 cells
transfected with pcDNA3,constitutively overexpressing S100P.
B. Western Blot analysis showing intracellular expression of S100P and f-actin in transfected
Rama 37 cells.
1: Rama 37 cells transfected with pcDNA3 Empty vector.
2: Rama 37 T-25cells transfected with the T-Rex Inducible system with S100P cDNAbut
nottreated with doxycycline.
3: Rama 37 T-25 cells induced to express S100P by treatment with doxycycline (67.5 nM)
for 72 hours.
4: Rama 37 cells transfected with S100P cDNA in pcDNA3.
¢. Table showing the relative amount of intracellular S100P extracted from induced Rama 37
T-25 cells with doxycycline for 72 h and for Rama 37 cells transfected with S100P cDNA in
pcDNA3.Standard deviation were calculated from three separate qPCR experiment and three
separateblots.
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To find out whether the human inducible system behaved in the same way
as the rat inducible system, the induction of S100P was carried out on the HeLa A-9
cells. QPCR experiments showeda significant 10-fold upregulation of S100P mRNA
after 72 h of 112.5 nM doxycycline treatment (p= 0.001, Student's t test) (Figure 3.6
C), which shows that the human inducible system behave similarly to the rat
inducible system, with a similar fold induction of mRNA.
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Figure 3.5. Stimulation of intracellular production of S100P protein in inducible HeLa A-9
cells.
A.
B.
Western Blot analysis showing intracellular expression of S100P and f-actin in transfected
HeLa A-9 cells (1) with or without (2) a 72 h of 112.5 nM doxycycline treatment.
Histogram showingthe relative amount of S100P protein compared to B-actin protein detected
by Western Blot in transfected HeLa A-9 cells (1) with or without (2) a 72 h of 112.5 nM
doxycycline treatment (Student's t-test, * p < 0.05).
Quantitative RT-PCR showing relative expression levels of S100P mRNA in HeLa A-9 cells
after and before 72 h of doxycycline treatment. Expression levels were measured from cell
cultures isolated at 0 h andafter cultivation in doxycycline (112.5 nM) treated medium for 72
h. The results were first normalised to the housekeeping mRNAfor B-actin. Finally, expression
was compared to untreated HeLacells transfected with T-Rex inducible system).
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3.2.2. Intracellular S100P stimulates cell migration in vitro
3.2.2.1. Rat mammary cells
To investigate potential effects of S100P on rat mammary cell migration,
chemotactic analysesin vitro were performed with cells overexpressing intracellular
S100P. Migration was measured using cells over a 24 h period in Boyden chambers
(as described in Materials and methods Section 2.2.1.2.). Assays were first
performed with pcDNA3-S100P cells using Rama 37 pcDNA3-e asa control. Results
showed a significant increase in migration of cells overexpressing S100P (8.6%)
(Figure 3.6) compared to S$100P-negative Rama 37 pcDNA3-e cells (2.7 %; p =
0.00017, Student's t test).
Further analysis of the effects of S100P on cell migration were carried out
with Rama 37 cells transfected with the inducible system. Migration was
determined over the time periods of 0-24 h or 48-72 h of doxycycline treatment.
Cells were seeded in the Boyden chamberat time0 h orat 48 h. 24 h of doxycycline
treatmentis the time period which I have shown by Western blotting to produce an
appreciable quantity of S100P (Figure 3.7) in the Rama 37 T-25.
Cell migration assays showed a higher percentage of migratingcells in the
periods 0-24 h and 48-72 h in the presence of doxycycline and induction of S100P
(Figure 3.7 A) than in the absenceof the inducer. 24 h after addition of doxycycline,
cell migration increased 4.6 fold compared to cells not exposed to doxycycline.
There wasalso an increase 72 h after addition of doxycycline over those cells not
treated with doxycycline, but it was less 3.9 fold. This reduction in doxycycline
enhancementof migration is due to a slight increase in the number of migrating
cells in the uninducedcultureat later times of culture. The difference in migration in
24 h between doxycycline-treated and non-treated controls is highly significant at
either time (p = 0.005 at 24 h and 0.002 at 72 h, Student's t-test, Figure 3.7 B).
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Figure 3.6 Stimulation by intracellular S100P of migration in the Rama 37 cell lines
constitutively overexpressing S100P.
A. Histogram showing the mean percentage of migratory cells constitutively overexpressing
intracellular S100P (grey bar), and cells non expressing S100P (white bar). Data show the
mean +/- Standard Deviation (S.D.) from three separate experiments.
B. Table showing Student's t-test results between cells non-expressing S100P andcells expressing
S100P (* p < 0.05).
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Figure 3.7 Stimulation by intracellular S100P of migration in Rama37 T-25 cell lines.
A. Histogram showing the meanofpercentage ofmigratory cells treated with 67.5 nM doxycycline
(red bars) for 24 h and 72 h, and untreated cells (white bars). Data show the mean +/- Standard
Deviation (S.D.)from three separate experiments.
Table representing Student's t-test results between untreated and doxycycline-treated cells (* p
< 0.05).
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3.2.2.2. Humancells
Effects of S100P on human cell migration were investigated with HeLa A-9
cells transfected with the inducible system. As previously described, migration was
determined over a 24 h period of doxycycline treatmentstarting at 0 h or 48 h. The
percentage of migratingcells at 24 h and 72 h increased comparedto untreated cells
24 h and 72 after addition of doxycycline and induction of S100P (Figure 3.8 A). 24
h after addition of doxycycline, cells have significantly increased their migration 2.8-
fold compared to cells not exposed to doxycycline, and 72 h after addition of
doxycycline there was still a 2.8-fold increase of treated cells over those left
untreated. The migration difference between doxycycline-treated and non-treated
controls is highly significant at either time (p= 0.003 at 24 h and 0.002 at 72 h,
Student'st-test, Figure 3.8 B).
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Figure 3.8 Stimulation by intracellular S100P of migration in HeLa cell lines
overexpressing S100P.
A. Histogram showing the mean of percentage of migrating cells overexpressing intracellular
S100P (grey bar) after 72 h of doxycycline treatment (112.5nM), and untreated cells not
expressing S100P (white bar). Data show the mean +/- Standard Deviation (S.D.) from three
separate experiments. .
B. Table showing Student’s t-test results between cells non-expressing S100P and cells
overexpressing S100P (* p < 0.05).
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3.2.3. Intracellular Distribution of S100P
Overexpression of S100P has been detected in several cancers such as breast
(Guerreiro DaSilvaet al., 2000), colon (Birkenkamp-Demtroderet al., 2005), prostate
(Averboukh et al., 1996), pancreatic (Logsdonetal., 2003) and lung (Diederichs etal.,
2004). This protein has also been functionally implicated in carcinogenic processes
such as cellular immortalisation (Guerreiro DaSilvaet al., 2000). The role of S100P
implication could be dependent on its subcellular location. Nuclear, cytoplasmic,
and extracellular location of S100P is evident in the vast majority of S100P
expressing cells (Arumugam etal., 2004; Fuentes et al., 2007; Wang et al., 2006).
Thus, in this section, the subcellular distribution of S100P following its induction
with doxycycline in the T25 cells has been examined.
3.2.3.1. Subcellular distribution of induced S100P
Intracellular localisation and level of S100P in Rama 37 cells was examined
by immunohistochemistry to show the subcellular distribution of S100P protein
expression at the microscopic level (as described in Materials and methods Section
2.2.1.4.a.). The immunostaining corroborated the Western blot data, whereby the
level of S100P protein in cells treated with doxycycline was muchhigherthan that in
untreated cells (Figure 3.9). In untreated Rama 37 T-25, few cells showed the
presence of detectable S100P (Figure 3.9 A a). In Rama 37 T-25cells treated with
doxycycline (67.5 nM), intracellular S100P was detected from 24 uptoatleast 96 h
(Figure 3.9 A b-e), consistent with the Western blotting data (Figure 3.2). 63% of total
cells after 24 h, increasing to 80% after 48 h, 89% after 72 h and decreasing to 78% at
96 h (Figure 3.9 B).
Quantification of the intracellular distribution of S100P between cytoplasm
and nucleus in the T-25 cells (Figure 3.9 B) revealed that in untreatedcells, after 48 h,
5% of the cells showed the presence of S100P in the cytoplasm and 5% S100P in the
nucleus, but this staining might be due to non-specific antibody staining or to a
minimum of S100P protein undetectable by Western blotting. In contrast, when T-25
cells were treated with doxycycline, S100P waspresentin the cytoplasm of 52% of
cells at 24 h, 30% at 48 h, 48% at 72 h and only 34% at 96 h of S100P induction
(Figure 3.9 B). Nuclear S100P staining was significantly detected after 24 h of
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treatment, but only in less than 10% oftotal cells (p = 0.021, Student's t-test between
nuclear staining of untreated cells and cells treated with doxycycline (67.5 nM) for
24 h). However, the proportion of nuclear staining cells increased to 50% at 48 h (p =
0.0002, Student's t-test, compared betweencell treated for 24 and 48 h and remained
at more than 40% (p < 0.0001, Student's t-test, comparison betweencells treated for
72h and 96 h) at both 72 h and 96 h of doxycycline treatment. In contrast to the
nuclear staining, the proportion of cells exhibiting cytoplasmic staining of S100P,
highly significantly increased to 50% of cells at 24 h (p = 0.0002, Student's t-test
between cytoplasmic staining of untreated cells and treated with doxycycline (67.5
nM) for 24 h) but then significantly decreased to only 30% at 48 h (p = 0.001,
Student's t-test), and then significantly increased again to 50% of cells (p < 0.0002,
Student's t-test), and after 96 h of treatment, the number of cells with S100P
cytoplasmic staining once again significantly decreased to less than 40% (p= 0.0002,
Student'st-test) (Figure 3.9 B).
In the above analysis, cells stained for both cytoplasmic and nuclear were
classified as nuclear stained, since a translocation of S100P to the nucleus was
observed. The presence of S100P going to the nucleus raises the question of a
potential role in gene expression. When cells were untreated, nearly all cells were
unstained at any time, but after treatment even if there werestill a high proportion
of unstained, it decreased during the time course, 38% after 24 h (p < 0.0001,
Student’st-test), 20% at 48 h (p < 0.0001, Student'st-test), and a minimum of 11% at
72 h (p <0.0001, Student's t-test). After 96 h of treatment there wasa slightly higher
level with 20% of cells unstained (p < 0.0001, Student'st-test).
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Figure 3.9 Intracellular S100P protein expression in inducible Rama 37 T-25 cells detected
by immunohistochemistry.
A. Imunocytochemicalstaining for S100P of inducible Rama 37 T-25 cells for untreated cells and
treatedcellsfor 96 h with 67.5 nM of doxycycline. The stain was cytoplasmic (arrowheads) and
nuclear (arrows).
(Magnification: x40; Bar 12 um.)
B. Histogram representing percentageof cells after S100P immunohistochemical detection. White
bars show unstainedcells, black bars show an S100P nuclearcell staining, and grey bars show a
cytoplasmic S100Pcell staining.
(* p < 0.05)
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S100P was additionally detected by immunofluorescence to compare the
presence of intracellular S100Pafter activation of the inducible system by treatment
with doxycycline in Rama 37cells (67.5 nM) and HeLacells (112.5 nM) (Figure 3.10).
No S100P wasdetected before treatment (Figure 3.10 A1), and S100P was detected in
Rama 37 T-25 treated cells for 72 h (Figure 3.10 Az) with 35% of S100P nuclear
staining (p < 0.0001, Student's t-test analysis between untreated cells and treated
cells for 72 h with doxycycline (67.5 nM)) and 55% of cytoplasmic staining (p <
0.0001, Student's t-test analysis between untreated cells and treated cells for 72 h
with doxycycline (67.5 nM)). Results accorded with previous observations (Parkkila
et al., 2008; Rehbein et al., 2008; Sato and Hitomi, 2002; Tongetal., 2010; Wangetal.,
2006; Whiteman et al., 2007). More types of cell lines were analysed by
immunofluorescencein order to find out whether the presence of nuclear S100P was
just a feature of the inducible Rama 37 cell lines. Rama 37cell lines constitutively
expressing S100P were examined for nuclear and cytoplasmic S100P. In Rama 37
pcDNA3-e cells, no intracellular S100P was detected (Figure 3.10 Bi) but was
detectable in 90% of Rama 37 pcDNA3-S100Pcell cultures constitutively expressing
S100P. Staining analysis revealed 30% of nuclear staining (p < 0.0001, Student's t-test
analysis between S100P expressing and non-expressing cells) and 60% of
cytoplasmic staining (p < 0.0001, Student's t-test). The proportion of nuclear staining
is consistent with that of 44% obtained using the inducible Rama 37 system after the
sameperiod of 72 h.
Human HeLa A-9 cells transfected with the inducible systems were also
analysed by immunofluorescence, and again untreated cells did not reveal any
S100P (Figure 3.10 C;). Immunofluorescence was apparent after treatment (Figure
3.10 C2), although at an apparently lowerlevel than in the pCDNA-3 and T25cells,
with 40% of unstained cells after 72 h of doxycycline treatment (112.5 nM), 15% of
nuclear staining and 45% of cytoplasmic staining. In summary, intracellular
expression of S100P could be induced in the two entirely independentcell lines
transfected with a S100P cDNAinserted in an inducible system sensitive to
doxycycline.
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Figure 3.10 Immunofluorescence microscopy showing expression of
intracellular S100P protein.
A. Immunofluorescence for S100P in Rama 37 cells transfected with the inducible system.
Az. Untreated Rama 37 cells.
Az. Rama 37 cells treated for 72 h with doxycycline (67.5 nM) to activate intracellular
S100P production.
B. —Immunofluorescencefor S100P in Rama 37 cells transfected with a pcDNA3vector.
B,. Rama 37 cells transfected with a pcDNA3vector only
Bo. Rama 37 cells transfected with a pcDNA3containing a S100P cDNA sequence.
C. Immunofluorescence for S100P in HeLacells transfected withthe inducible system.
C;. Untreated HeLacells
Co. HeLa cells treated for 72 h with doxycycline (112.5 nM) to activate intracellular S100P
production.
(Magnification: x50)
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Observations confirmed the ability of S100P to translocate to the nucleus.
Different degrees of translocation have been observed between Rama 37 cells, and
HeLa cells showing higher nuclear S100P presencein rats cells rather than Human
cells. All these observations combine to suggest that S100P might have a potential
nuclear function. Furthermore these observations will be important to help us
understand and characterise the intracellular effects of S100P.
3.2.4. Discussion
Literature indicates that S100P is an active constituent of cancer phenotype
(Birkenkamp-Demtroderet al., 2005; Parkkila et al., 2008), associating an over-
expression of S100P with tumour progression and development (Arumugam etal.,
2005; Basu et al., 2008; Diederichs et al., 2004), and most importantly, S100P
stimulates health degradation by inducing tumourcells to metastasise (Wanget al.,
2006). Distant metastasis is the primary cause of death in cancer patients, and an
important step in the metastatic process is the migration of tumour cells into
surroundinghosttissue.
To characterise the properties of S100P protein I usedcells transfected with a
single inducible transgene vector that confers site-specific expression after
doxycycline induction. IIn this study I have suitably checked for any leakiness,
which wasnotsignificant and the uninducedcells did not stimulate cell migration.
Doxycycline is 6-deoxy-5-oxy tetracycline antibiotic, synthesized from
oxytetracycline by a series of sequential steps that produce methacycline and
eventually doxycycline (Nelson, 1998). Reports have described that doxycycline
produces someeffects on cancercells in vitro and in vivo (Fife and Sledge, 1995; Fife
and Sledge, 1998). It inhibited cell proliferation and apoptosis induction and
tumours growth in breast carcinoma cells (Fife et al., 1994). It inhibited cell
proliferation, apoptosis induction and tumours growth in breast carcinoma cells
(Fife et al., 1994), but low concentrations have been described notto have anyeffect
on cancercells (Onodaetal., 2006; Sourdeval et al., 2006).
Myinvestigations clearly demonstrate that overexpression of intracellular
S100P significantly stimulates cell migration in the rat mammary (Rama 37 T-25)
and human cervical cancercell lines (HeLa A-9). This demonstrates a direct role for
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S100P in one crucial aspect of metastasis: cell migration. I first observed cytoplasmic
staining for S100P after induction of S100P, and staining for S100P in the nuclei is
strongly detected after three days of intracellular expression. My observations
showed,as previously reported (Wanget al., 2006; Whiteman etal., 2007), that when
S100P is over-expressed in cells, it is translocated to the cell nucleus. I therefore
speculate that for invasive carcinomas overexpressing S100P, S100P transcription is
somehow activated and elevated S100P protein mediates the invasive phenotype.
Therefore, in the next chapter I focused on S100P’s intracellular influence on gene
transcription using DNA chip microarrays to compare gene expression between
S100P non-expressing and overexpressing Rama 37 T-25 cells. This study is followed
up by quantitative real-time PCR and SiRNAsilencing of any promising
upregulated gene that maybe involvedin cell migration.
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4.1. Introduction
Literature indicates that S100P is an active constituent of the cancer
phenotype (Birkenkamp-Demtroderetal., 2005; Parkkila et al., 2008), associating an
overexpression of S100P with tumour progression and development (Arumugam et
al., 2005; Basu et al., 2008; Diederichs et al., 2004), and most importantly, S100P
stimulates health degradation by inducing tumour cells to metastasise (Wangetal.,
2006). Distant metastasis is the primary cause of death in cancer patients, and an
important step in the metastatic process is the migration of tumourcells into
surroundinghosttissue.
Initially, S100P was isolated from trophoblast cells, in the placenta, which
strongly express S100P. However S100P is weakly expressed in adult tissues,
including heart, lung skeletal muscle, spleen and leucocytes, but is highly expressed
in neoplasmic tissues (Parkkila et al., 2008). S100P has been shown to induce
metastasis in rats and to be associated with tumour metastasis aggressiveness and
worst patient prognosis in several types of cancer including breast and pancreatic
(Arumugam etal., 2005; Wanget al., 2006). Therefore several observations support a
role of S100P in invasive growth and metastasis of cancers. Immunostaining of
tumours overexpressing S100P demonstrated a strong presence of nuclear S100P,
raising the question of a potential role on gene expression associated to its potential
metastasis-promoting functions.
Mystudies in Chapter 3 have indicated a significant association of S100P
expression and cell migration, and a strong expression of nuclear S100P. The
hypothesis to be tested in this chapter is whether the nuclear S100P affects the
expression of other genes. To studythis, I have used the transfected inducible Rama
37 T-25cell line to allow the analysis of variations in gene expression arising from a
change in only one parameter, namely, the increased expression of intracellular
S100P. In orderto identify possible target genes of S100P, oligonucleotide microarray
technology was employed to highlight genes that were differentially expressed
between Rama 37 cells treated with doxycycline for 72 h and untreated cells. The
aim of these studies is to identify genes in which mRNA expression was
significantly changed betweencells expressing S100P andcells not expressing S100P.
Microarray findings would be backed up by qPCR studies and an up-regulated
induced gene by overexpression of S100P will be suppressed byits specific SiRNA
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to assess its potential to regulate cell migration potentially associated to cell
migration.
4.2. Results
4.2.1. Identification of genes associated with S100P overexpression by
DNAchip microarray
To identify genes associated with the stimulation of cell migration by S100P, I
compared gene expression between induced Rama 37 T-25 cells overexpressing
S100P and uninduced Rama 37 cells not expressing S100P by oligonucleotide
microarrays. To capture subtle differences and to avoid confounding factors I used
cells transfected with the inducible system and studied cells the sametreated cells
with doxycycline and non-treated cells.
Microarray data analysis with the Bayesian statistics at a p value < 0.05 (as
described in Chapter 2 2.4.4.), yielded list of 55 up-regulated (Table 4.1a-b) and 45
down-regulated genes (Table 4.2a-b). After False Discovery Rate (FDR) analysis to
explore the elimination of false positives and negatives independent of the number
of samples being tested (Storey and Tibshirani, 2003), the adjusted p value < 0.05
revealed a list reduced to only 7 differentially expressed genes, 5 were up-regulated
and 3 down-regulated with at least a 3-fold difference in expression between non-
expressing uninduced and induced overexpressing S100P Rama 37 T-25cells. All the
up-regulated genes have been associated with cancer progression. Folate Hydrolase
1 (Folh1), also known as Prostate-specific Membrane Antigen (PSMA), a type II
glycoprotein, which is highly overexpressed in prostate cancer (Nosset al., 2002;
Sweatet al., 1998) is associated with poor patient prognosis (Perneret al., 2007),
and is implicated in endothelial cell invasion and angiogenesis by modulating
integrin signalling (Conwayetal., 2006).
Akr7a2 (aldo-keto reductase family 7, member A2) is a dimeric succinic
semialdehyde (SSA) reductase, previously characterised as aflatoxin aldehyde
reductase (Schaller etal., 1999), which has been reported to be highly expressed in
renal (O'Connoret al., 1999) and pancreatic cancers (Cui etal., 2009) and has
been proposed as a potential biomarker candidate for pancreatic cancer (Cuietal.,
2009).
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proliferation (Andoet al., 1993). Overexpression has been correlated with gastric
Cyclin D2 (Ccnd2) protein regulator of the Cyclin dependent kinases CDK
(Gi to S phase cell cycle transition (Morgan, 1997) known to be importantin cell
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In thefirst data list containing 55 up-regulated genes, before FDR analysis, I
observed potentially interesting genes such as S100A7a an isoform of another
member of the S100 protein family (Kulski et al., 2003; Wolf et al., 2003). The
microtubule associated serine threonine kinase 1 (Mastl), which is a cytoskeletal
associated kinase (Valiente et al., 2005; Walden and Cowan, 1993). The pituitary
tumor-transforming 1 interacting protein (Pttglip), a protein facilitating nuclear
translocation of transcription factor pituitary tumour transforming factor (Pttg1)
(Chien and Pei, 2000), and myc target 1 (Myctl) a protein binding the c-Myc
oncogene, whichis implicatedin cell proliferation (Tsuneokaet al., 2002).
Among the list of down-regulated gene, one is involved in muscle
contraction, the myosin heavy chain 8 (Myh8). The FCH domain only 1 (Fcho1)is
involved in clathrin-coated vesicle formation (Sakaushi et al., 2007), and the Zinc
finger, NFX1-type containing 1 (Znfx1), is binding to the X-box motif of major
histocompatibility complex (MHC)classII genes.
I decided to analyse this panel of 7 up-regulated gene products, containing 3
significantly differentially expressed genes with adjusted p values less than 0.05
(Folh1, Akr7a2 and CcnD2), and 4 genes with borderline adjusted p values
(S100A7a, Masti, Myct1 and Pttglip) and validate them by quantitative real-time
PCR(Table 4.3).
82
Chapter 4 Epigenetic Modification/ Regulation by Overexpression of S100P
 
Adjpsaenie Gene name Genbank Locus Gene Functions valuesymbol accession No <0.05
Prostate-specific
Folh1 ‘Folate hydrolase 1 NM_057185 1q32 membrane Yes
antigen
Aldo-keto Detoxification of
Akr7a2 reductase family NM_134407 5q36 aldehydes and Yes
7, member A2 ketones
Cend2 Cyclin D2 NM_022267  4q42_--Regulationofcell =v,proliferation
$100 calcium
S100A7a_ binding protein NM_001109471 2q34 Inflammation No
A7A
microtubule Interaction with
MAST1 associated serine/ NM_181089 19q11_ syntrophin on No
threonine kinase the cell surface
Myctl  MycTarget1 NM_001106207 ip Pinding to Myc Nooncogene
Pituitary tumor-
transforming 1 Pttg]Pttglip : . NM_001013238 20p12 translocation Nointeracting into nucleus
protein
Table 4.3 List of up-regulated genes in Rama37cells after S100P overexpression evaluated
by DNAchip microarray.
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4.2.2. Validation of microarray results
Using qPCR I measured the relative transcript levels of differentially
expressed mRNAtranscripts to validate these observations for an extendedlist of 7
candidate genes (Folh1, Akr7a2, Ccnd2, S100A7a, Mast1, Myctl1 and Pttglip), which
have been shown to be expressed in the literature in different cancer types, and
could be a target for investigations within a potential association with the S100P
metastasis- promoting protein.
Results showed that S100P was up-regulated 13 fold in Rama 37cells treated
with doxycycline for 72 h compared to untreated controls incubated for the same
time (Figure 4.1), confirming the overexpression of intracellular S100P in Rama 37
T-25 cells. Based on the microarray results, it was expected that Folh1 and Akr7a2
would be up-regulated about7 fold in S100P overexpressedcells, but only a 1.3 -fold
change for Folh1 and 4-fold for Akr7a2 compared to control was observed, which
was lower than observed by microarray but wasstill differentially expressed (P =
0.012, Student t-test comparison Folh1 relative mRNA between uninduced and
induced cell with doxycycline (67.5nM). There were distinct differences in the
expression among these genes by qPCR analysis, however validated the microarray
results. The following 2 up-regulated genes observed from the extendedlist by
microarray were validated by qPCR. S100A7a and Mast1, were 5.5 and 4.5 fold up-
regulated by qPCRin cells treated with doxycycline for 72 h compared to untreated
cells, which were notsignificantly differently expressed in the microarray results. As
expected, it was found that after Gapdh normalisation, either of the Nrip3, Myct1
and Pttglip showedsignificant regulation (Figure 4.1).
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B S100P Mast1 Akr7a2 Ccnd2 Folhl S100A7a
Genes Amplification fold Standard al
(Mean) Deviation p vatue
S100P 13.42 2.2 < 0.0001
Mast 1 4.56 0.9 0.006
Akr7a2 3.79 0.6 0.004
Ccnd2 4.2 1.6 0.031
Folh 1 1.28 0.4 0.004
S100A7a 1.96 0.6 0.034
Pttglip 0 / 0.234
Myct 1 0 / 0.384
 
Figure 4.1 qPCR validation of differentially expressed genes observed by microarray in
Rama37transfected cells using the inducible system treated with doxycycline (67.5 nM)
for 72 h.
A. Relative quantity mRNA level were measured by gPCRin untreated andtreated cells for 48 h.
Final transcripts data were normalised to GAPDHdata. Values shown are mean normalised
value + SD, Student's t-test was performed by comparison between the absence or presence of
S100P induction by doxycycline treatment (67.5 nM)for 72 h.
B. Table represents fold amplification of analysed genes, with calculated p values between the
absence or presence of S100P induction by (67.5 nM) doxycycline treatment for 72 h. Data
show the mean +/- Standard Deviation (S.D.) of technical triplicates from three separate
biological experiments.
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A % 7
=&<S5o=aE<
B S100P Mast 1 Akr7a2  Ccnd2 Folh1 S100A7a
Gene , Standardsymbol Validated Mean fold change Deviation p value
S100P Yes 17.4 2.4 0.028
Mast1 Yes 3.7 0.4 0.0007
Akr7a2 Yes 4.5 1.7 0.023
Ccnd2 Yes 3.8 1.2 0.016
Folh1 Yes 1.6 0.4 0.007
S100A7a Yes 3.2 0.7 0.006
Myct 1 No 0 / 0.49
Pttglip No 0 / 0.81
 Figure 4.2 qPCR analysis of differentially expressed genes observed by microarray in
Rama 37 pcDNA3-e and pcDNA3-S100P
A. Relative mRNA levels were measured by gPCR between Rama 37 pcDNA3-e, transfected with
an empty vector, and Rama 37 pcDNA3-S100P transfected with S100P cDNA. Final
transcripts data were normalised to relative GAPDH levels and are represented as
amplification fold change of transcripts. Data show the mean +/- Standard Deviation (S.D.) of
technicaltriplicatesfrom three separate biological experiments.
Mean amplification fold change of analysed genes over GAPDHtranscripts. Student t-test
comparison between the absence (pcDNA3-e) or presence (pc-DNA3-S100P) of S100P cell
intracellular expression: ifp< 0.05, validated (Yes), ifp> 0.05 not validated (No) (Student's t-
test).
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I then used Rama37 cells constitutively expressing S100P to confirm the
differentially expressed genes previously observed, using Rama 37 constitutively
overexpressing S100P (pcDNA3-e and pcDNA3-S100P). Similar results were found
with significant up-regulation of Folh1 (2 fold change) Akr7a2 (4.5 fold change), and
Ccnd2 (4 amplification fold) (Figure 4.2). From the extended list Mastl (4 fold
change) and S100A7a (3 fold change) were shown to be up-regulated, and Nrip3 ,
Pttglip and Myctl were confirmed in a second cell line not to be differentially
expressed.
In summary,of the 3 genes identified from thestatistical analysis of the DNA
chip microarray data: Folh1, Akr7a2 and Ccnd2,all were validated by qPCR in both
transfected Rama 37 cells either transfected with the inducible system or with
pcDNASvector. 2 other genes, Mast1 and S100A7a have been found up-regulated as
well in all S100P-expressing Rama37cells tested.
4.2.3. Treatment with Mastl specific SiRNA decreases in vitro cell
migration in Rama 37 cells overexpressing S100P
Among the up-regulated genes, Mastl the gene coding for Microtubule-
Associated Serine-Threonine kinase 1, has been confirmed to display the highest
fold change in the inducible system. Therefore, Mastl was chosen for further
analysis to investigate whether an increase in cell migration was a direct
consequenceof the effects of S100P on Mast1. Members of the MASTprotein family,
composed of 5 members (Mast1-4 and Mast-like) are characterised by the presence
of a serine/threonine kinase domain and harbours both a kinase domain and a PDZ
scaffolding domain (Walden and Cowan, 1993). PDZ is an acronym combining the
first letters of three proteins, post synaptic density protein (PSD95), Drosophila disc
large tumour suppressor (DIgA), and zonula occludens-1 protein (zo-1). The PDZ
domain is an important interaction module for proteins involved in many
intracellular pathways and abnormalactivations, and membersof the Mast family,
specifically, have been shown to bind and stabilise the tumour suppressor
phosphatase, PTEN via its PDZ binding domain (Valiente etal., 2005). In rats, Mast1
has been shown to be expressed in several tissues such as heart, brain, spleen, lung,
liver, skeletal muscle, kidney andtestis (Garlandet al., 2008) and is associated with
cytoskeleton organisation by its interaction with and B2-syntrophin microtubules.
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The role of Mast1 in its interaction and mechanism of action in cell migration, is
unknown therefore I used Rama 37 constitutively expressing S100P cells to
determine whether S100P’s influence with Mastl1 was direct and its role in cell
migration.
- Transfection efficiency
Rama 37 pcDNA3-S100P cells were seeded in 24 well plate with Mastl
specific SIRNAor scrambled SiRNA transfected along with BLOCK-IT Alexa Fluor
Red Fluorescent Oligos, and after cell washing, intracellular fluorescence was
observed microscopally to ensure successful probe transfection. After a 12 h
incubation with the Hiperfect lipofection solution (Qiagen) more than 90% of both
cell lines were stained positive for BLOCK-IT.
- Genesilencing efficiency
Five SiRNA probes sequences were ordered from Qiagen: Rn_Mastl_1,
Rn_Mast1_2, Rn_Mast1_3 and Rn_Mast1_4 andthe efficacy of SIRNAs against the
target Mast1 gene, was determined by qPCR of Mast1 mRNA.Fora better silencing
efficiency result, all SIRNA probes were transfected together, and the degradation of
target mRNAwastested. The mRNAexpression levels were evaluated by qPCR.In
order to compare the potency of these SiRNAs, their gene-silencing-activity was
assayed using dose-response curves. Prior to transfection, the synthetic SiRNAs
were mixed with the Hiperfect transfection reagent and incubated at room
temperature to allow the formation of transfection comeplexes, according to the
manufacturer’s recommendations. Transfections were carried out according to Chap
2. 2.5.3. in 48-well dishes. SIRNA probes were transfected into 6 x 104 Rama 37
pcDNA3-S100P cells at concentrations ranging from 1 to 10 nM.After 48 h of
incubation at 37°C, cells were harvested and Mastl mRNA levels were assayed
(Chap 2. 2.5.4). Stable suppressed expression of Mastl in Rama 37 pcDNA3-S100P
cells was observed after 48 h (Figure 4.3), with a 83% of gene knockdown after
addition of 5 nM Mastl1 probes each, and 87% knockdown with 10 nM. No
significant Mastl gene expression suppression was observed using an Allstar
negative control at any concentrations of Mast1 probes.
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Figure 4.3 Dose-response curve of SiRNA concentration against percentage of Mast1
mRNAsilencing
The silencing activity of Mast1 was monitored by qPCR (Chap 2.5.3.). mRNA levels were
normalised to those ofGAPDH mRNA.
SiRNAswere transfected into Rama 37 pcDNA3-S100Pcells at various concentrations (1-
10 nM)for 48 h represented by black squares for Mast1 oligos and represented by white diamonds for
Allstar negative control. Error bars show the standard deviation calculated from the mean of 3
separate experiments.
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Pretreatment with SiRNA targeting Mast 1 inhibits mRNAand protein expression. Rama
37 cells grown in cultures were transfected with SiRNA targeting Mast1 for 48 h. Shown are
quantitative qPCR and Western Blot analysis ofMast1 mRNAafter 48 h of transfection with 10nM
SiRNA.Data were normalised to B-actin
A. Graph showing the mean percentage of Mast 1 mRNAincells constitutively overexpressing
intracellular S100P, treated with 10nM SiRNA probes (control and Mast 1). Data show the
means +/- Standard Deviation (S.D.) from three separate experiments (*** p < 0.001).
B. Mast1 protein detected by western blot of Rama 37 cells transfected with Control SiRNA(-)
and Mast 1 SiRNA (+)
C. Histogram showing the amount of Mast1 protein relative to that of B-actin. Data show the
mean +/- Standard Deviation (S.D.) of technical triplicates from three separate biological
experiments.
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4.2.4. Effects of MAST1 mRNAknock-down oncell migration
These results were confirmed at the protein level by Western blotting for
Mast1 which detected a protein at around 205 kDa (Figure 4.4). After SIRNA
treatment for 48 h Mast1 expression was down-regulated with a decrease of 90% in
gene expression observed by qPCR. (Figure 4.4 A). Mast1 gene was down-regulated.
at both mRNAandprotein levels by transfection of Mast1 SiRNA probes in Rama 37
cells overexpressing high endogenous S100P levels (Figure 4.4 B). Similarly, Mast1
protein expression was reduced dramatically at 72 h post-transfection and persisted
at 5 days (Figure 4.4 B).
To examinethe effects of Mast1 on cell migration, Mast1 gene expression was
suppressed and migration has been assayed in Boyden chambers between 24 and 48
h after addition of Mast1 SiRNAsilencing (Figure 4.5). Percentage of migratory cells
untransfected with SiRNA probes is similar to the level of cells transfected with
SiRNA Allstar control with about 8% of cells migrating through the membrane
(Figure 4.5 A). After silencing of Mast1 expression the numberofcells significantly
dropped to 3% despite the presence of S100P (Student's t-test, p = 0.00532). Results
show that the presence of S100P alone wassufficient to stimulate cell migration but
expression of both proteins was neededfor the stimulated responsein cell migration
(Figure 4.5B).
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Figure 4.5 Effect of MAST1 mRNA knockdownoncell migration
Boyden chamber assay ofRama 37 constitutively expressing S100Pwas measuredfrom cells
pretreated with SiRNA probes for Mast 1 and controls. Results shown are from triplicate wells for
each sample, performed three times.
A. Bar chart showing the mean ofpercentageofcells treated with 10 nM ofMast 1 SiRNA probes
(red bars) for 72h, and cells treated with SiRNA control, which does not target any gene
product (white bars). Data show the means +/- S.D. from three separate experiments.
B. Table representing Studentt-test results between Mast 1 SiRNA treated and SiRNA control
treated cells (** p = 0.00532, Student’s t-test comparison between cell transfected with Mast1
SiRNA andtransfected with control probes).
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4.3. Discussion
In order to examine the hypothesis that S100P affects the pattern of gene
expression, I examined the differential gene expression influenced by S100P
overexpression in the S100P inducible Rama 37 cell line by microarray. Five genes
shown to be up-regulated by microarray have been confirmed to be differentially
overexpressed in S100P constitutively overexpressed rat mammary cell lines (Rama
37) and in S100P inducible human cells (HeLa). Among these genes, some have been
shown to be up-regulated previously in cancer and associated with cancer
progression, namely, Folh1, CcnD2, and S100A7 (Mermelshtein et al., 2005; Perner et
al., 2007; Takanoet al., 1999; Tripathi et al., 2010). However, Akr7a2 and Mast1
confirmed by my own qPCR experiments to be up-regulated, have so far been
indirectly associated with cancer or metastatic activity.
In my study, Mast1 SiRNAi resulted in potent silencing of Mast1 expression
at the mRNAandprotein level. My results suggest that Mast1 is necessary for rat
mammary cell migration in cultured cells. The exact mechanism by which Mastl
stimulates migration is poorly understood. It has been speculated that Mastl
binding to PTEN, via the PDZ domain may be important in the control of PTEN’s
tumour suppressor function (Valiente et al., 2005). In my results knock down of
MAST1 is strongly associated with reduced cell migration, and suggest direct
involvement of S100P in Mast1 up-regulation. Thus Mast1 is probably positioned
downstream of S100P in the pathway which leads to increased cell migration in
S100P overexpressingcells.
Mast1 intracellular interactions or binding have not been analysed. Mast1
harbors a PDZ domain known to play several indispensable cellular and biological
roles, such as in cell adhesion, growth, developmentand polarisation, suggesting
Mast1 has several cellular applications. Mast1 activation by S100P induces cell
migration. Myresults do not differentiate as to Mast1 up-regulation was caused by
intracellular or extracellular S100P (Figure 4.7). Therefore since S100P
overexpression led to Mastl gene up-regulation and increase of cell motility.
However, some $100 proteins occurs outside the cell (Schmidt-Hansenet al., 2004).
Thus raising the possibility of an alternative mechanism for intracellular up-
regulation of Mastl gene expression by a nuclear transcriptional influence or
extracellularly via a potential cell surface receptor (RAGE?) (Figure 4.7). Thus, to
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explore the extracellular activity hypothesis, I analysed the extracellular activity of
S100P.
Migration
  
Figure 4.7 Illustration of hypothesised S100P ‘s role in stimulating Rama37 cell migration.
S100P overexpression in Rama 37 cells up-regulates Mast1 gene expression, and
induces cell migration. The mechanism of S100P in inducing Mast1 is totally unknown. One
hypothesis is that S100P is secreted to the extracellularly and activate receptors, the second is that
S100Pis translocated into the nucleus and acts to stimulate Mast1 transcription.
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5.1. Introduction
Several S100s proteins have been shown to be released from the cell and
different extracellular functions have been described in recent years. For example
S100A7, which wasfirst observed as a protein highly upregulated in lesions of
psoriatic skin (Madsenet al., 1991). It is excreted from cells during inflammation
andacts as chemotactic factor for keratinocytes (Boniface et al., 2005) and leukocytes
(Wolf et al., 2008) by activation of the RAGEreceptor. S100A8 and S100A9are also
highly expressed in the extracellular matrix, and are associated with extracellular
chemostatic stimulation of neutrophils to inflammatory sites (Ryckman et al., 2003;
Wolf et al., 2008). Furthermore S100A13 is involved in the release of extracellular
fibroblast growth factor-1 (FGF-1), interleukin-1-a, and to act as a cargo molecule by
binding nuclear Prothymosin-a (ProTa) (Landriscina et al., 2001; Mandinovaet al.,
2003; Matsunaga and Ueda, 2008; Matsunaga and Ueda, 2010). The metastasis-
inducing S100A4 protein has also been reported to be translocated outside the cell
(Novitskayaet al., 2000) and to bind to the RAGE receptor (Yammani et al., 2006).
Although nothing is known aboutthe excretion mechanism, S100P is found
to be secreted to the extracellular compartment despite the lack of a conventional
secretory signal sequence. Accumulation of extracellular S100P has been reported to
have an influence on cell functions, such as cell proliferation and survival
(Arumugam etal., 2004). The RAGE receptor has been identified as a target for
several $100 proteins, including S100P (Arumugam etal., 2004; Schmidtet al., 2001).
RAGE is 35 kDa protein of the immunoglobulin-like cell surface receptor
superfamily. It is composed of three extracellular domains, a “V” (Variable) type
immunoglobulin-like domain followed by two “C” (Constant) type domains, a
single transmembrane-spanning helix, and a short cytosolic domain (Neeperetal.,
1992) (Figure 5.1). Additional RAGE isoforms lacking the transmembrane and
cytosolic regions (soluble RAGE (sRAGE)) (Park et al., 2004) or the “V”
immunoglobulin domain (NtRAGE) (Yonekuraet al., 2003) have beenidentified in
human brain suggesting isoform-specific functions for the receptor (Figure 5.1).
Structure-function studies have shown that the V-domain is critical for ligand
binding and that the cytosolic tail is essential for RAGE-mediated intracellular
signalling. A truncated form of RAGE, whichlacks thecytosolic tail, but remains
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embedded in the membrane, can bind ligands but it acts as a dominant negative
(“DN-RAGE”) receptor.
PI3K/AKT and extracellular signal-regulated kinase 1/2 (ERK1/2)
signalling pathways are two important kinase cascades that have been reported to
be activated by the RAGE receptor and to induce invasion and metastasis
(Arumugam etal., 2004; Arumugametal., 2005; Leclerc etal., 2007). S100P has been
shown to be secreted from cancerous cells and to stimulate through the RAGE
receptor ERK1/2 activation, which increased cell proliferation, migration survival
and tumour growth (Arumugametal., 2004; Arumugam et al., 2005). Activation of
the PI3-K/AKT signalling pathway by S100P has never been described, but is
associated with multiple human cancers. AKT (protein kinase B) is a serine/
threonine kinase, which wasinitially identified as a viral oncogene and is composed
of three isoforms, AKT1, AKT2, and AKT3, with differing levels of tissue expression
and function (Bellacosaet al., 1991). PI3K activation of AKT is a multistep process
beginning with PI3K phosphorylating phosphatidylinositol-4,5-bisphosphate to
phosphatidylinositol-3,4,5-triphosphate. AKT’s binding to these phosphoinositides
results in its relocation from the cytoplasm to the plasma membrane (Coffer etal.,
1998). Phosphorylation of AKT at two distinct sites leads to its activation (Feng et
al., 2004; Franke et al., 2003). Studies reported that direct PI3K activation was
sufficient to disrupt epithelial polarisation and induce cell migration and invasion
(Keely et al., 1997).
In the present project, a series of experiments were performed to determine
whether extracellular S100P can affect cell migration and if so which receptor might
be involved. I explored whether extracellular S100P was able to modulate Mitogen-
activated protein kinase (MAPK) and Phosphoinositide 3-kinases (PI3K) activities in
Rama 37 and HeLacells, and analysed the their potential role on cell motility.
Analysis consisted of the addition of extracellular S100P onto Rama 37 and HeLa
cells, and examination ofintracellular kinases phosphorylation.
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Figure 5.1 Schematic representation of RAGEreceptorstructure and ligandinteraction.
RAGEis composed of an extracellular three immunoglobulin-like regions: One “V”-type
followed by two “C”-type, a single transmembrane-spanning domain and a 43-aminoacidcytosolic
tail (not drawnto scale).
A truncated form of RAGE, which lacks the cytosolic tail and remains firmly embedded in
the membrane is competent to bind the usual complement of RAGEligands, but acts as a dominant
negative receptor termed “DN-RAGE”, and its expression strikingly suppresses RAGE-mediated
signalling, even in cells bearing the full-lengthform.
The soluble RAGE (sRAGE) is a C-truncated form of full-length RAGE, which lacks a
cytoplasmic tail and a transmembrane domain.
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5.2. Results
5.2.1. S100P can translocate outside of cells
In order to find out whether the intracellular S100P finds its way into the
medium, immunoblots were performed on medium from cultures of S100P
expressing induced Rama 37 T-25 cells and HeLa A-9 cells. As shown in Figure 5.2,
S100P wasnot detected in the culture medium ofcell-free control plates, which only
contained culture medium extracted from plates treated with (67.5 nM) or without
doxycycline (Figure 5.2 a). Similar negative results were found in the medium from
untreated Rama 37 T-25 and HeLa A-9 cells (Figure 5.2 b-c), which do not express
S100P protein. However different sized S100P oligomers were detected in the
culture media of doxycycline-treated Rama 37 T-25 (67.5 nM) and HeLa A-9 (112.5
nM) cells overexpressing intracellular S100P (Figure 5.2 d-e, respectively).
Extracellular oligomers of S100P sized between 21 to 80 KDain size were detected in
the culture medium from the induced Rama 37 T-25 and HeLa A-9 cell lines. S100P
octamers at around 80 kDa were the most prominent oligomers detected in induced
Rama 37 T-25 cells (Figure 5.2 d), whilst S100P dimers (21 kDa) and tetramers (40
kDa) were the most abundantoligomers in the medium of induced heLa A-9 cells.
A possible monomer band at 10 kDa was present in the medium from the human
cells (lane e), but was absent in the medium from theratcells (lane d). Although
differences were foundin the distribution of different sized oligomers betweenrat
and human cells, nevertheless both cell lines produced larger S100P oligomers
outside the cell and retained S100P in the form of monomers and dimersinsidecells
(Figure 5.3).
Within cells, most S100 family members exist in the form of antiparallel
packed homodimers (sometimes heterodimers), capable of binding two homologous
or heterologous target proteins in a Ca**- dependent manner (Donato, 2001).
However $100 oligomers can form, under the non-reducing conditions found in the
extracellular space (or within cells upon changesin thecells redox status) (Ilg et al.,
1996) which may explain why I detect only S100P oligomers outsidecells.
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Figure 5.2 Identification of S100P in the extracellular medium of S100P positive and
negativecells.
S100P oligomers were detected in the culture medium by immunoprecipitation 24 h after
doxycycline treatment (67.5 nM).
a. Detection of S100P by immunoprecipitation of 1 ml of culture medium treated with
doxycycline (67.5 nM) extractedfrom cell-free controlplate.
Detection of S100P by immunoprecipitation of 1ml culture medium (67.5 nM) extracted from
a plate growing untreated Rama 37 T-25 cells.
Detection of S100P by immunoprecipitation of Iml culture medium treated with doxycycline
(112.5 nM) extractedfrom untreated HeLa A-9 cells.
Detection of S100P by immunoprecipitation of 1ml culture medium treated with doxycycline
(67.5 nM) extractedfrom Rama 37 T-25cells overexpressing S100P.
Detection of S100P by immunoprecipitation of 1ml culture medium treated with doxycycline
(112.5 nM) extractedfrom HeLa A-9cells overexpressing S100P.
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Figure 5.3 S100P intracellular expression of cells overexpressing S100P
a. S100P-induced Rama 37 T-25 whole cell extract assessed by Western blottingfor S100P using
polyclonal anti-S100P.
b. S100P-induced HeLa A-9 cells whole cell extract S100P detection assessed by Westernblotting
analysis using polyclonal anti-S100P.
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5.2.2. Extracellular role of S100P
Purified recombinant S100P (rS100P) protein was added to the Rama 37 T-25
cell culture medium, and the resulting cellular responses to stimulation by
extracellular S100P proteins, such as increased cell migration, and activation of
receptor and signalling pathways were investigated.
5.2.2.1. Extracellular S100P can stimulate cell migration
Increasing concentrations of purified rS100P were added to the culture
medium of S100P negative Rama 37 T-25 uninduced cells and cell migration was
analysed over a 24 period by in a Boyden chamber.After 24 h in control assays in
which no S100P was added to the culture medium only 1.7 % of cells migrated
through to the lower chamber (Figure 5.4 A). No significant differences were
observed after addition of 5 nM S100P, since 1.8 % of cells were motile (p =0.7,
Student'st-test). However when 10 nM exogenous S100P as addedto the uninduced
Rama 37 T-25 cells, this resulted in a significant increasein cell migration to 2.9% of
motile cells (p = 0.0003, Student’st-test)(Figure 5.4 B). The optimal concentration of
extracellular S100P protein required to stimulate uninduced Rama 37 T-25 cell
migration was 100 nM,with a significant 7.5 % of cells passing to the lower
chamber, (p = 0.0001, Student’s t-test) (Figure 5.4 B). Addition of higher
concentrations of exogenous S100P to uninduced Rama 37 T-25 cells still showed a
significant increasein cell migration over noadditions atall although the numberof
motile cells decreased to 6.1 % with 500 nM S100P (p = 0.002, Student's t-test) and to
4.5 % with 1000 nM of S100P addition (p= 0.006, Student'st-test) (Figure 5.4 B).
Nosignificant difference in the proportion of migratory cells was observed
between S100P added extracellularly to Rama 37 T-25 S100P uninducedcells and to
induced intracellular S100P expressing (without addition of rS100P) Rama 37 cells (p
= 0.051). This suggests that the extracellular effects of S100P on cell migration at
these high concentrations may besimilar to these produced by the induced Rama 37
T-25cells.
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Figure 5.4 Stimulation of cell migration in the S$100P negative, uninduced Rama 37 T-25
cell line.
A. Histogram of the percentage of migrating cells caused by increasing concentrations of S100P
addedto the extracellular medium.
B. Table showing Student's t-test between cells where no S100P was added and addition of S100P
(0-1000 nM). Data show the mean +/- Standard Deviation (S.D.) from three separate
experiments.
(* p < 0.05) Data arefrom three independent experiments.
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Similar increasing concentrations of rS100P (0-1000 nM) were added to the
culture medium of S100P negative HeLa A-9 uninducedcells and cell migration was
analysed over a 24 h period in a Boyden chamber. After 24 h only 2.1 % ofcells
migrated through to the lower chamber in control assays (Figure 5.5 A). No
significant differences were observed after addition of 5 nM S100Psince only 2.1 %
of cells were motile (p = 0.2, Student'st-test). However addition of 10 nM exogenous
S100P resulted in a significant increase in migration to 3.7 % of motile cells (p =
0.002, Student's t-test)(Figure 5.5 B).
The optimal concentration of extracellular S100P protein required to
stimulate uninduced HeLa A-9 cell migration was 100 nM,a concentration similar to
that observed in Rama 37 T-25cells, with a significant 8.3 % increase ofcells passing
to the lower chamber (Figure 5.5 A) (p = 0.0003, Student's t-test) (Figure 5.5 B).
Addition of higher concentrations of rS100P (500-1000nM) showeda significant
increase in cell migration stimulation over that without any additions; was 8.1 %
with 500 nM (p = 0.0001, Student's t-test) 6 % with 1 mM of S100P addition (p =
0.0002, Student’s t-test) (Figure 5.5 B).
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Figure 5.5 Stimulation of cell migration in the S100P negative, uninduced HeLa A-9 cell
line.
A. Histogram of the percentage of migrating produced by increasing concentrations of S100P
added to the extracellular medium. Data shows the means +/- Standard Deviation (S.D.) from
three separate experiments.
B. Table showing Student's t-test results between cells where no S100P was added and addition of
S100P (0-1000 nM)(* p < 0.05, Student'st-test).
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5.2.2.2. Addition of Extracellular S100P stimulates the AKT signalling
pathway
Previous experiments revealed that addition of extracellular S100P to the
Rama 37 T-25 and HeLa A-9 uninducedcells significantly increased cell migration
(Figures 5.4 and 5.5). I next examined the effect of similar concentrations of
extracellular S100P on cell migration signalling pathways. The serine/threonine
kinase AKT (also called protein kinase B) (Staal et al., 1977) is well known to be an
important regulator of cell survival (Brunetet al., 1999) and growth and has also
been shown to promote cell migration in different organisms (Kim et al., 2001) and
to be activated by specific phosphorylations in breast cancer tissues (Bose etal.,
2006).
In the present experiments, treatment of Rama 37 T-25 cells with
extracellular S100P induced phosphorylation of AKT in a time-dependent manner
(Figure 5.5 A). Addition of 100nM Extracellular S100P (shownpreviously to be the
optimal concentration to stimulate significant cell migration), induced AKT
phosphorylation within 20 min (p = 0.001), and a maximal increase over control
levels was observed after 60 min (p = 0.000006) (Figure 5.5 B). AKT phosphorylation
levels declined after 60 min (Figure 5.5 B).
The effects of S100P on phosphorylation of AKT were also concentration-
dependent, with significant effects noted 60 min after addition of 10 nM rS100P with
a 0.3 relative amount of pAKT (p = 0.0006, Student's t-test) and maximal effects
noted with 200 nM S100P anda 0.8 relative amount of pAKT (p = 0.00001, Student’s
t-test) in the uninduced Rama 37 T-25cells (Figure 5.6).
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Figure 5.6 Addition of extracellular S100P stimulates AKT phosphorylation in a time-
dependent-mannerin uninduced Rama 37 T-25 cells.
Purified S100P was added to the culture ofRama 37 T-25cells. Cells were lysed and analysed for the
presence ofpAKT(Ser*”) by Western blotting.
A. Western Blot showing the induction ofAKT phosphorylation in uninduced Rama 37 T-25cells
treated with extracellular rS100P (100 nM) for the indicated times (0 -90 min).
B. Histogram showing the amountofpAKTrelated to AKT.
C. Table showing Student's t-test results between cells where no S100P was added and addition of
S100P (100 nM). (Student's t-test, * p < 0.05). Data show mean + S.D from three independent
experiments.
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Figure 5.7 Addition of extracellular S100P stimulates AKT phosphorylation in a
concentration-dependent-mannerin uninduced Rama37 T-25 cells.
Purified S100P was added to culture medium of uninduced Rama 37 T-25cells. Cells were lysed 60
min after addition ofS100P and analysedfor the presence ofpAKT (Ser*’’) by Western blotting.
A. Western Blot showing the increase ofAKT phosphorylation in uninduced Rama 37 T-25cells
after 60 min of treatment with extracellular rS100P for the indicated concentrations (0 -500
nM).
B. Histogram showing the amountofpAKTrelative to AKT.
Table showing Student's t-test results between cells where no S100P was addedandaddition of
S100P (0-1000 nM).
(Student's t-test, * p < 0.05) Data show mean + S.Dfrom three independent experiments.
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Whenextracellular rS100P (100 nM) was added to HeLa A-9cells, it induced
AKTphosphorylation within 10 min, and a maximalincrease over control levels (0.7
pAKT/total AKT ratio) was observed after 45 min (Student'st-test, p = 0.0001). AKT
phosphorylation levels declines after 60 min (Figure 5.7 B). Different concentrations
of S100P were addedto the culture medium of uninduced HeLa A-9 cells. There was
a concentration-dependent phosphorylation of AKT with significant effects noted at
10 nM and maximal effects noted with 500 nM S100P 60 min after addition of S100P.
Thus when extracellular rS100P was added to uninduced Rama 37 T-25 and HeLa
A-9 show there wasa time-dependentand concentration-related phosphorylation of
AKT.
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Figure 5.8 Addition of extracellular S100P stimulates AKT phosphorylation in a time-
dependent-mannerin uninduced HeLa A-9cells.
Purified S100P was added to the culture of HeLa A-9 cells. Cells were lysed and analysed for the
presence ofpAKT(Ser*’3) by Western blotting.
A. Western Blot showing the induction of AKT phosphorylation in uninduced HeLa A-9 cells
treated with extracellular rS100P (100 nM) for the indicated times (0 -90 min).
B. Histogram showing the amountofpAKTrelated to AKT.
Table showing Student's t-test results between cells where no S100P was added and addition of
S100P (100 nM). (Student's t-test, * p < 0.05). Data show mean + S.D from three independent
experiments.
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Figure 5.9 Addition of extracellular S100P stimulates AKT phosphorylation in a
concentration-dependent-mannerin uninduced HeLa A-9cells.
Purified S100P was added to culture medium of uninduced HeLa A-9 cells. Cells were lysed 60 min
after addition of S100P andanalysedfor the presence ofpAKT (Ser*”’) by Western blotting.
A. Western Blot showing the increase ofAKT phosphorylation in uninduced Rama 37 T-25cells
after 60 min of treatment with extracellular rS100P for the indicated concentrations (0 -500
nM).
B. Histogram showing the amountofpAKTrelative to AKT.
Table showing Student's t-test results between cells where no S100P was added and addition of
S100P (0-1000 nM)
(Student's t-test, * p < 0.05) Data show mean + S.Dfrom three independent experiments.
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5.2.2.3. Addition of extracellular S100P stimulates the ERK 1/2 signalling
pathway
Extracellular signal-regulated kinases (ERKs) are members of the mitogen-
activated protein kinase (MAPK)family, which play pivotalroles in diverse cellular
events such as regulatingcell proliferation, survival (Kim etal., 2009), and migration
(Jo et al., 2002). Furthermore S100P has been reported to stimulate ERKs in a mouse
embryonic fibroblast cell line (NIH 3T3) through the RAGE Receptor (Arumugam et
al., 2004), as well as in the SW480 colon cancer cell line (Fuentes et al., 2007).
Activated ERKs phosphorylate numerous cytoplasmic, cytoskeletal proteins (Yoon
and Seger, 2006), microtubule cytoskeleton (Reszkaet al., 1995) and nuclear targets
including transcription factors (Janknecht, 1996; Wanget al., 2004; Zhaoetal., 2003).
Therefore a pathological deregulation of ERKs signalling pathway can result in
dramatic consequences to cell homeostasis. Thus different concentrations of
exogenous S100P were addedto the cell culture medium, andcell lysates were
analysed for ERK (Thr202/Ty1r204) phosphorylation by Western blotting.
Whenextracellular rS100P (100 nM) was added to uninduced Rama37 T-25
cells, it induced ERK phosphorylation within 5 min (0.45 pERK 1/2 /f-actin ratio, p
= 0.007, Student's t-test) and a maximal increase over control levels (0.8 pERK 1/2 /
B-actin ratio) after 30 min (Figure 5.10). ERK 1/2 phosphorylation levels declined by
25 % at 45 min (0.6 pERK 1/2 /f-actin ratio). The Effect of S100P on ERK (Thr202/
Tyr204) phosphorylation is time-dependent(p = 0.002, Student's t-test).
Furthermore, extracellular rS100P (100 nM) was added to HeLa A-9 cells
culture medium, and induced ERK phosphorylation within 5 min, with a 0.6 pERK/
B-actin ratio and a maximal increase overcontrollevels (0.7 pERK/f-actin ratio) was
observed after 45 min (Figure 5.11 B). ERK phosphorylation levels declines beyond
60 min. A time-dependant AKT phosphorylation was induced by extracellular
S100P addition to non-expressing Rama 37 T-25 and HeLa A-9 cell lines
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Figure 5.10 Addition of exogenous S100P stimulates phosphorylation of ERK in
uninduced RamaT-25cells
Purified S100P (100 nM) was added to the culture medium of uninduced Rama37 T-25cells for 45
min.
A. Western Blot showing the increase of ERK (Thr202/Tyr204) phosphorylation in uninduced
Rama 37 T-25 cells treated with extracellular rS100P (100 nM)for the indicated times (0 -90
min).
B. Histogram showing the amount ofpERK 1/2 relative to that ofB-actin.
C. Table showing Student's t-test results between cells where no S100P was added and addition of
S100P (100 nM). (Student’s t-test, * p < 0.05). Data show mean + S.D from three independent
experiments.
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Figure 5.11 Addition of exogenous S100P stimulates phosphorylation of ERK in
uninduced HeLa A-9 cells
Purified S100P (100 nM) was addedto the culture medium ofuninduced HeLa A-9cellsfor 45 min.
A. Western Blot showing the increase of ERK (Thr202/Tyr204) phosphorylation in uninduced
Rama 37 T-25 cells treated with extracellular rS100P (100 nM)for the indicated times (0 -90
min).
B. Histogram showing the amountofpERK 1/2 relative to that ofB-actin.
C. Table showing Student's t-test results between cells where no S100P was added and addition of
S100P (100 nM). (Student's t-test, * p < 0.05). Data show mean + S.Dfrom three independent
experiments.
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5.2.2.4. S100P mediated PI3K/AKT and MEK/ERK activation is RAGE-
dependent
Since exogenous S100P wasaddedto the culture medium,it activated PI3K/
AKT and MEK/ERKsignalling pathways, this prompted us to investigate whether
these pathways could be regulated by the RAGEreceptor. To determine, whether
the addition of extracellular S100P activates PI3K/AKT and MEK/ERK pathways
through the RAGEreceptor, anti-RAGE inhibitor was used to block the ligand-
RAGEreceptor binding (as described in the Material and Methods Chapter 2
Section 2.2.1.1.g.).
Thus uninduced Rama 37 T-25 cells were treated with Anti-RAGE (166yg/
mL) for 30 min, before rS100P (100nM) was addedto the cells, and enzyme in the
signalling pathway analysed with time. Whencells were treated with Anti-RAGEI
observed an inhibition of the increase phosphorylation of both ERK (Thr202/
Tyr204), at anytime up to 60 min (p = 0.302, Student's t-test) (Figure 5.9). The
increase of phosphorylation of AKT (Ser*”’) was also inhibited at anytime up to 60
min (p = 0.777, Student's t-test) (Figure 5.9). Presumably the blockage of S100P
binding to RAGEbyantagonists inhibited the phosphorylation and henceactivation
of the PI3K/AKT and MAPK/ERK signalling pathways (Figure 5.9). Thereafter
phosphorylation of PIS3K/AKT and ERK1/2 was observed after 60 min presumably
because inhibition by the anti-RAGE receptor declined perhaps due to its
degradation. The increase phosphorylation of AKT was still inhibited up to 1440
min (p = 0.119, Student’s t-test) (Figure 5.9). Nevertheless, after 1440 min the
increase of phosphorylation of ERK 1/2 was significant (p = 0.007, Student'st-test).
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Figure 5.12 Effect of treating uninduced Rama37 T-25 cells with Anti-RAGEinhibitor (166
ug/mL)
Uninduced Rama 37 T-25cells were treated with Anti-RAGE inhibitor (166 ug/mL) for 30 min prior
addition of rS100P (100 nM) for 60 min
A. Western Blot showing the induction of ERK (Thr202/Tyr204) and AKT (Ser*”*)
phosphorylation in uninduced Rama 37 T-25 cells treated with extracellular rS100P (100 nM)
and Anti-RAGEforthe indicated times (0 -1440 min).
B. Histogram showing the relative amount of pERK 1/2 relative to B-actin (white bars) and the
amountofpAKTrelative to AKT(grey bars).
C. Table showing Student's t-test results between Rama 37 T-25 cells treated with Anti-Rage
(166 ug/mL) where no S100P was added and addition of S100P (100 nM). (Student's t-test, * p
< 0.05). Data show mean + S.Dfrom three independent experiments.
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5.2.2.5. S100P stimulates cell migration through AKT and ERK 1/2
signalling pathwayvia the RAGE Receptor
To investigate whether the effects of extracellular S100P on cell migration
were mediated via the RAGEreceptor and the AKT and ERK pathways,I attempted
to block its effect with the anti-RAGE antibody anda specific inhibitor of the AKT
pathway, wortmannin and of the ERK pathway, PD98059. Wortmannin is a specific,
covalentinhibitor of phosphatidylinositol 3-kinases (PI3Ks), which has been isolated
as an antibiotic from a culture of the fungi Penicillium wortmanni Klocker (Brian etal.,
1957). The fungal metabolite wortmannin is an inhibitor, which show fairly high
specificity for PI3K. Wortmannin binds to the p110 catalytic subunit of PI3K,
noncompetitively and irreversibly inhibiting the enzyme (Powis et al., 1994).
A dose-response curve was assessed for wortmannin, in order to use the
most efficient inhibitory concentration of the enzyme for my migration assay
(Figure 5.10). The treatment of uninduced Rama 37 T-25 with 100nM wortmannin
before the addition of rS100P (100 nM) to the culture medium decreased by 80 % the
phosphorylation of pAKT, 60 min after addition of rS100P (Figure 5.10 A). Higher
concentration of wortmannin inhibited the 90 % of AKT phosphorylation, but to
limit cytotoxic effect that could be dueto the use of high concentration of inhibitor, I
used 100 nM wortmannin for my migration assay.
I also used PD98059, which is a synthetic non-competitive inhibitor of the
ERK 1/2 MAP kinase cascade (Pang et al., 1995). A dose-response curve was
assessed for PD98059 so that I could use use the most efficient inhibitory
concentration of the enzymefor mycell migration assay (Figure 5.10 B).
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Figure 5.13 Dose-response curve of Wortmannin and PD98059 concentration against
Realtive amount of phosphorylation of pAKT and pERK
A. The inhibition activity of pAKT was monitored by increasing concentration of wortmannin
inhibitor. pAKTlevels were normalised to those ofAKT.
B. The inhibition activity of pERK was monitored by increasing concentration of PD98059
inhibitor. pERKlevels were normalised to those of B-actin.
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The migration assay was performed in the Boyden chambers, and migratory
stimulation by extracellular S100P (100nM) with or without inhibitor treatment.
After 24 h in control assays in which no S100P was added to the culture medium
only 1.7 % of cells migrated through to the lower chamber. When 100 nM exogenous
S100P protein was added to the uninduced Rama 37 T-25cells, this resulted in a
significant 7.5 % increase of cell motility passing to the lower chamberafter addition
of (p = 0.0001, Student's t-test) (Figure 5.11 A). Treatment of Rama 37 T-25 cells with
wortmannin (100 nM) inhibited cell migration with no significant difference
proportion of migratory cells observed with 1.7 % of motile cells before addition of
100 nM S100P and 2.3 % of motile cells after addition of 100nM (p = 0.2, Student'st-
test). The inhibition of AKT phosphorylation significantly abolished the S100P
extracellular induction of cell migration. No significant difference of motile cells (p =
0.8, Student's t-test) was observed after inhibition of phosphorylation of ERK1/2
with PD 98059 (50nM) treatment. Only 1.5 % of motile ininduced Rama 37 T-25cells
were observed before S100P was added to thecells, and 1.6 % motile ininduced
Rama 37 T-25 cells after exogenous rS100P (100 nM) addition. Similar results were
observed with treatment of uninduced Rama 37 T-25 cells with Anti-Rage when
only 2.2 % of cells were motile prior addition of exogenous rS100P and no
significant difference (p = 0.08, Student's t-test) of motile cells was observed with 3.2
% motile cells when S100P was addedto the medium.
These results suggest that the extracellular effects of S100P on cell migration
is RAGE-dependent and activates both MEK/ERK 1/2 and PI3K/AKT signalling
pathways.
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Figure 5.14 Effect of inhibitors wortmannin, PD98059 and RAGE anitibodies on
extracellular S100P-induced migration in Rama37 T-25 cellline.
A. Histogram of the percentage of migrating cells stimulated with (red bars) or without (white
bars) extracellular rS100P (100 nM)in the presence (+) or absence (-) ofan inhibitor treatment.
Data show the mean +/- Standard Deviation (S.D.) from three separate experiments.
B. Table showing the presence (+) or absence(-) ofinhibitor treatments
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5.3. Discussion
The extracellular appearance of S100P outside thecell as previously reported
in the literature (Arumugam etal., 2004) has been confirmed in Rama 37 cells and
HeLa cells. In this chapter, it is reported that the presence of S100P is correlated with
cell migration through PI3K/AKT and MAPK/ERK 1/2 by the Rage receptor. Both
pathwaysare critical for Rama 37 and HeLacell migration, with significant decrease
of migration when inhibited. Other member of the S100 protein family have been
shown to stimulate AKT phosphorylation, such as S100A7, which has been
correlated with phosphorylated AKTin breast invasive carcinomas (Emberleyetal.,
2005) via NF-xB regulation though IxB inhibition (Emberley et al., 2005). Moreover,
in the previous chapter (Chapter 4) microarray results highlighted S100A7a, an
isoform of S100A7, to be up-regulated by S100P, however in this study the cross-
talks of the S100A7, AKT and NF-xBhasnot been investigated.
PI3K is activated downstream of extracellular signals and phosphorylates
phosphatidylinositol-4,5-bisphosphate to generate phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which is a lipid second messenger, which activates the
phosphorylation of AKT. A tumour suppressor is known to play an important role
pAKT phosphorylation regulation: Pten (phosphatase and tensin homologue
deleted on chromosome 10) (Tokunagaet al., 2007). The tumour suppressor PTEN
catalyses the opposite reaction by reducing the pool of PIP3. The PI3K/AKT
pathway alteration is commonly associated with the tumour-suppressor Pten
deregulation in human malignancy (Marty et al., 2008). Abnormal PI3K and PTEN
regulation is a strong indicator of metastasis and poor patient survival in breast
carcinomas (Marty et al., 2008; Saal et al., 2007). I have not investigated the
implication of PTEN in the S100P cell migration inducing process.
Furthermore I have shown that the knock-down of Mast1 gene in Rama 37
pcDNA-S100P cells overexpressing S100P significantly decreased cell migration
(Chapter 4), and despite the extracellular addition of S100P, no cell migration was
activated, showing an important combination of S100P-Mast1 regulator activity
direct role of Mast1 on the extracellular. The hypothesis of a downstream regulation
of the RAGEreceptoroncell migration, such as the inactivation of AKT and/or ERK
downstream pathways via MAST1 up-regulation S100P, as represented in the
illustration Figure 5.13.
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Figure 5.13 Illustration of the role of extracellular S100P in Rama 37 T-25 stimulated cell
migration
It’s suggested that extracellular S100P activatescell migration via PISK/AKT and ERK 1/2 /
MAPKsignalling pathways through the RAGE receptor. The stimulated migration was
abolished after treatments of induced Rama 37 T-25 cells with inhibitor that blocked RAGE
receptor and AKT and ERK 1/2.Intracellular S100P up-regulates Mast1 expression, which
is also involved in cell migration (Results Chapter 4), and knock-down of Mast1 gene
expression, despite addition ofextracellular S100P significantly decreases cell migration.
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GENERAL DISCUSSION
The ultimate goal of this study has been to identify new molecular markers
associated with cell migration induced by up-regulation of S100P and further verify
experimentally, the role of these markers. To characterise the role of the metastatis-
inducible calcium-binding protein S100P’s role on cell activity I used cells
transfected with a single inducible transgene vector that confers site-specific
expression after induction with doxycycline. This approach of the use of a single
cell-type specific doxycycline-inducible construct for in vitro studies over the
conventional knock-out or overexpression of a specific gene has several advantages,
including ability to turn S100P on or off as desired, giving more accuracy in the
detection of potential targets for S100P. For further investigations in rats,
administration of oral doxycycline is easy to perform compared to the intra-
peritoneal administration of other inducers such as tamoxifen and it also generates
less side effects. Some disadvantages of doxycycline-inducible strategies have been
reported, such as possible leakiness in un-induced cells, or when the cDNA was
used instead of the genomic sequence, normal post-transcriptional modifications
suchasalternative splicing may not take place due to lack of introns in the sequence
(Meyer-Ficca et al., 2004; Pham et al., 2008). Doxycycline is 6-deoxy-5-oxy
tetracycline antibiotic, synthesized from oxytetracycline by a series of sequential
steps that produce methacycline and eventually doxycycline (Nelson, 1998). It has
been reported to have effects on cancer cells in vitro and in vivo (Fife and Sledge,
1995; Fife and Sledge, 1998). At higher (42 mM)concentrations it inhibited cell
proliferation, induction of apoptosis and growth of tumours in breast carcinoma
cells (Fife et al., 1994), but low concentration used here (62.5 - 112.5 nM) have been
reported to have noeffect on cancercells (Onodaet al., 2006; Sourdevaletal., 2006).
Our investigations using the S100P inducible cell line developed in our
laboratory by Dr G.Wang, demonstrates that intracellular overexpression of
intracellular S100P significantly stimulates cell migration in our rat mammary
(Rama 37) and human derived cervical cancer cell lines (HeLa). The results
demonstrated a direct role for S100P in cell migration.
Despite the fact that overexpression of S100P has been well documented in
numerous cancers, associated with tumour progression (Arumugam etal., 2005;
Bartling et al., 2007; Basu et al., 2008; Fuentes et al., 2007; Moussesetal., 2002), poor
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patient prognosis (Diederichs et al., 2004; Fuentes et al., 2007; Guerreiro Da Silva et
al., 2000; Logsdon et al., 2003; Mousseset al., 2002; Wang et al., 2006) and more
recently with induction of metastasis (Wanget al., 2006), the underlying cellular
mechanisms are obscure. The subcellular localisation of the protein in our cell
models wasin agreement with previously reported results i.e. it occurred in the cell
cytoplasm, nucleus and extracellular compartments (Parkkila, 2008; Sato and
Hitomi, 2002; Wanget al., 2006). S100P is naturally expressed in trophoblastic cells,
with a stronger expression in nuclei than in the cytoplasm (Parkkila et al., 2008), and
a similar nucleo-cytoplamic localisation has been detected in overexpression of
S100P in malignant tumour cells (Nakataet al., 2010; Parkkila et al., 2008; Rehbein et
al., 2008; Sato and Hitomi, 2002; Wangetal., 2006). The majority of normal cells do
not or only weakly express S100P, but after malignant transformationcells are often
found overexpressing intracellular S100P with a strong nuclear localisation. In one
study it is the nuclear S100P which is associated with a poor prognosis for breast
cancer patients. The association of patient death with nuclear S100P has been
observed for another S100 metastasis-inducing protein, S100A4 , with a poor patient
prognosis and poor response to chemotherapy diagnosis in advanced-stage ovarian
carcinoma (Maelandsmoetal., 2009). Wanget al. (2006) observed that in tumours
overexpressing S100P, it was principally localised in the nucleus, and the presence of
S100P expression has been strongly associated with a decrease of patient survival.
Nuclear localisation has been reported for several other S100 proteins:
S100A1 (Baudier et al., 1995), S100A4 (Flatmark et al., 2003), S100A5 , S100A6
(Deloulmeet al., 2000), S100A11 (Davey et al., 2000; Sakaguchi et al., 2000) and
S100B (Deloulme et al., 2000), but the translocation mechanism is poorly
understood. Since S100P is a small molecule of only 10.4 kDa (Beckeret al., 1992),
and doesnot contain any classical consensus sequences that could target the protein
to the nucleus, it could possibly pass through the nuclear pores without any active
transport mechanism being involved.
A number of microarray-based analyses have identified up-regulation of
S100P in various tumoral tissues. Our inducible system has allowed us to use cDNA
chip microarrays, to compare gene expression between migratory cells
overexpressing S100P and non-migratory cells not expressing S100P. This list of
differentially expressed genes contains 5 up-regulated genes and 3 down-regulated
genes. The up-regulated genes include Folate Hydrolase (Folh1), Cyclin D2 (CcnD2),
S100A7, aldo-keto reductase family 7 member A2 (Akr7a2) and a microtubule-
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associated serine/threonine kinase 1 (Mastl). The upregulations have been
confirmed by qPCR in our inducible rat mammary (Rama 37 T-25) and human cell
lines (HeLa A-9) and these results support the role of S100P in up-regulation of these
genes. All five up-regulated genes have been correlated with cancer progression,
invasion, poor prognostic or chemotherapyresistance. Folh1 (previously known as
the prostate specific-membrane antigen (PSMA)) is a type II metallo-peptidase
glycoprotein (Murphy et al., 1998; Pinto et al., 1996) commonly found to be
overexpressed in prostate (Sweatet al., 1998), including metastatic prostate cancer
(Changet al., 2001), gastric colorectal (Haffner et al., 2009), bladder (Gala etal.,
2000), and renal cancers (Dumasetal., 1999), and has been associated with poor
patient prognosis in patients suffering from endometrial carcinomas (Mhawech-
Faucegliaet al., 2008).
Studies have shown that the cyclin-dependent kinases D2, is overexpressed
in 20 breast carcinoma-derived cell lines (Buckley et al., 1993), in colon tumours,
where overexpression of Cyclin D2 is correlated with a higher TNM stage of the
cancer (Mermelshtein et al., 2005), and is also considered as a proto-oncogene due to
transcriptional activation of cyclin D2 in immortalisation of primary B lymphocytes
by the Epstein-Barr virus (Sinclair et al., 1994).
S100A7a is an isoform of the S100A7 protein (Kulski et al., 2003). S100A7 was
originally named psoriasin because it wasfirst identified as a pathophysiologically
active elementof psoriasis (Madsenet al., 1991). Studies have since found S100A7 to
be expressed in several tumoral tissues such as skin (Alowami et al., 2003), bladder
(Celis et al., 1996), stomach (El-Rifai et al., 2002) and breast (Al-Haddadetal., 1999;
Leygueet al., 1996; Moog-Lutz et al., 1995). S100A7 has also been associated with
poor prognosis of breast cancer patients (Emberley et al., 2003). Akr7a2 is an
aflatoxin B aldehyde reductase, which is involved in the detoxification of aldehydes
and ketones in phase I metabolism.It is also involved in metabolism of y-amino-
butyric acid by converting the succinic semi-aldehyde to y-hydroxybutyrate (Jez et
al., 1997; Jez and Penning, 2001). Akr7a2 has recently been reported to be highly up-
regulated in pancreatic cancer, but is not expressed in normal pancreas or benign
tumours.This result suggests a potential role for Akr7a2 in pancreatic tumour
pathological processes (Cuiet al., 2009).
Finally, Mast! is a cytoskeletal-associated kinase, which has been discovered
in the granule cells of the brain’s hippocampal dentate gyrus. These stem cells
proliferate to produce neuronal granule in the adult (Yano et al., 2003). Mastl is
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highly expressed in the brain and also in multiple tissues (Garland et al., 2008). It
binds syntrophin adapter proteins by PDZ-PDZ domain interactions. It have also
been reported that the Mast1 protein binds the tumour suppressor PTEN by PDZ-
PDZ interaction.It facilitates PTEN inactivation by phosphorylation (Valienteetal.,
2005). Up-regulation of these genes follows S100P up-regulation, and they are
therefore candidates for the S100P induction mechanism forincreasedcell migration
in our inducible systems. Thus I have shown that up-regulation of S100P in two
cancercell lines increases the expression of 5 genes described in the literature to be
active in tumorigenesis.
The up-regulation by S100P of a gene coding for a protein binding to the
microtubules, the microtubule-associated serine-threonine kinase 1 (Mast1),
suggests a potential role for Mast1 in cell migration. Thus it was of interest to
characterise its role further. So far Mastl has not been associated directly with
cancer or metastatic activity and its functions are largely unknown.In thisthesis
knock-out using SiRNA technology has been performed and our results
demonstrate a significant drop in cell migration when Mast] expressionis silenced
in rat mammary cells. Since there are no differences in levels of expression of S100P
mRNAafter knock-out of Mast1, this result suggests that there is no effect of Mast1
on S100P gene expression. Thus Mast1 is located downstream of S100P in the
induction of increased cell migration in our cellular systems. Our results
demonstrates a crucial involvement of Mast1 in S100P inducedcell migration, with
a significant 5-fold decrease in S100P induced cell migration despite the presenceof
S100P.
The data showsthat addition of extracellular S100P to the culture medium
also increased cell motility. S100P has been reported to interact with one commonly
described receptor, the Receptor for Advanced Glycation End-product (RAGE)
(Arumugametal., 2004; Fuenteset al., 2007). Activation of the RAGEreceptor has
been shown to stimulate cell growth, tumour progression and invasion via the
PI3K/MAPKintracellular signalling pathways (Arumugametal., 2005). Our results
corroborated these observations, since I observed enhanced Erk1/2 phosphorylation
after addition of 100 nM exogenous S100Pto the culture medium.This addition also
caused a significant increase (8 fold) in cell migration. I also described for the first
time the activation of the Akt pathway presumably by the same RAGEreceptor.
Thus addition of extracellular S100P activated Erk1/2 and Akt phosphorylation, and
their phosphorylation were inhibited by prior treatment of the cells with RAGE
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inhibitors and/or PD 98059. Cell migration stimulated by exogenous S100P wasalso
significantly decreased by 60% whencells were treated with Akt, Erk1/2 or RAGE
inhibitors. Thus extracellular S100P can stimulate cell migration in vitro though the
RAGEreceptoractivation of the PI3K/Akt signalling pathways.
Akt phosphorylation is an important initiator of a variety of oncogenic
processes, such ascell growth, proliferation, cell motility and invasion (Mitsiades et
al., 2004). Akt activation has been correlated with the loss or inactivation of the
PTEN tumour-suppressor in human patients and, in animal models, with increased
tumorigenicity and metastasis (Stiles et al., 2002). These results raise a possible
connection between the reduced functions of PTEN andits binding to Mast1 via
PDZ domains. This result could lead to AKT activation by the RAGEreceptor.
This hypothesis is supported by our results, which shows a decrease of AKT
phosphorylation after Mastl gene knockdown, despite the extracellular stimulation
of RAGE by exogenous S100P (Chapter 5). The present study clearly advances our
knowledge of potential molecules and pathways with which S100P can interact, but
presumably, some other unknown co-activators, such as non muscle skeletal
myosin, microtubules or tumour-suppressor, mayalso be involvedin cell migration.
Howeverit is clear that overexpression of S100P thenincreasescell migration.
Further investigation of S100P regulation of cell migration requires
multidisciplinary approaches to examine specific molecular interactions in vitro and
translate this information to S100P functions in vivo. Our microarray results revealed
an induction of transcription of 5 genes following intracellular stimulation of S100P
expression. I have targeted Mast1’s influence on cell migration, but more analysis is
required to clarify how this gene is regulated and potential S100P microtubule and/
or tumour suppressor binding partners. Investigations are also warranted to
determine, whether S100P nuclear localisation is due to the promoter or other
regulatory region of the binding Mast1 gene andactingas a transcription factor to
activate Mastl gene expression. Lastly, investigation to determine whether other
S100 proteins, which are structurally similar, are acting the same way to widen
patients presenting the same pathological features for potential targets against S100
metastasis-inducing proteins.
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S100P cDNA
Comments for pcDNA4™/TO
5078 nucleotides
 
CMVpromoter: bases 232-958
TATA box: bases 804-810
Tetracycline operator 2 (2X TetO2) sequences: bases 820-859
CMVForward priming site: bases 769-789
Multiple cloning site: bases 968-1069
c-myc epitope: bases 1073-1102
Polyhistidine (6xHis) tag: bases 1118-1135
BGHreverse priming site: bases 1158-1175
BGHpolyadenylation sequence: bases 1164-1388
f1 origin: bases 1434-1862
$V40 promoterand origin: bases 1867-2211
EM-7 promoter: bases 2253-2319
Zeocin™ resistance gene: bases 2320-2694
SV40 early polyadenylation sequence: bases 2824-2954
pUCorigin: bases 3337-4010 (complementary strand)
bla promoter: bases 5016-5114 (complementary strand)
Ampicillin (bla) resistance gene: bases 4155-5015 (complementary strand)
Figure A.1 peDNA4/TOinducible vector
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Comments for pcDNA6/TR
6662 nucleotides
CMV promoter: bases 232-819
Rabbit B-globin intron ||: bases 1028-1600
TetR gene: bases 1684-2304
$V40 early polyadenylation sequence: bases 2346-2477
f1 origin: bases 2897-3325
SV40 promoterand origin: bases 3335-3675
EM-7 promoter: bases 3715-3781
Blasticidin resistance gene: bases 3782-4180
SV40early polyadenylation sequence: bases 4338-4468
pUC-derived origin: bases 4851-5521
bla promoter: bases 6521-6625 (C)
Ampicillin (b/a) resistance gene: bases 5666-6526 (C)
Figure A.2 pcDNA6@/TR Regulatory plasmid
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   * There is an ATG upstream A-150228of the Xba |site. Bsml
Comments for pcDNA3:5446 nucleotides
CMV promoter: bases 209-863
T7 promoter: bases 864-882
Polylinker: bases 889-994
Sp6 promoter: bases 999-1016BGHpoly A: bases 1018-1249
SV40 promoter: bases 1790-2115
S$V40 origin of replication: bases 1984-2069
Neomycin ORF: bases 2151-2945
SV40 poly A: bases 3000-3372
ColE1 origin: bases 3632-4305
Ampicillin ORF: bases 4450-5310
Figure A.3. pcDNA3Expression plasmid
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Figure A.4 Chemical structure of wortmannin
O OCH3
Figure A.5 Chemicalstructure of PD 98059
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Figure A.6 Boxplots showing log2 expression values < 0.01 to 0.01 of microarray
Affymetrix analysis
Each box plot shows the different log2 expression values < 0.01 to 0.01 ofeach RNA sample
extracted from induced Rama 37 T-25 cells (72D, 72D1, 72D2) with doxycycline treatment
(62.5 nM)for 72 h, and RNAfrom uninduced Rama 37 T-25 (72N, 72N1, 72N2).
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Amplification Plot Mast1
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Amplification Plot Ccnd2
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Amplification Plot Pttglip
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Figure A.7 Amplification plots for qPCR targeted genes in induced and
uninduced Rama 37 T-25 cells
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Average
Target Relative
gene quantity
(Rq)
S100P 13.42 + 1.8
 
Mastl 4.56 + 0.98
Akr7a2 3.79 + 0.64
CcnD2 4.241.12
Folh1 1.28 + 0.38
S100A7a_ 55.52 + 0.81
Pttglip 1.12 + 0.2
Myctl —-1.28 + 0.38
Table A.1 QPCRrelative quantification data for targeted genes in induced and
uninduced Rama37 T-25 cells for S100P expression
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Amplification Plot GAPDH
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Amplification Plot Mast1
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Amplification Plot Ccnd2
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Figure A.8 Amplification plots for qPCR targeted genes in pcDNA3-empty and
pcDNA3-S100P Rama 37cells
143
Appendix
Target
gene
S100P
Mast1
Akr7a2
CcenD2
Folhi
S100A7a
Pttglip
Myct1
Average
Rq
17.6 +24
3.7 £ 0.4
4.5+1.2
3.8 41.4
1.6 + 0.4
3.2 + 0.7
0.98 +
11+
Table A.2 QPCRrelative quantification data for targeted genes between
Rama 37 pcDNA3-S100P and pcDNA3-empty cells
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Figure A.9 Amplification plots for qPCR targeted genes in induced and
uninduced Rama37 T-25 cells
 
Target Average Average Average Average Average Average
Ct ACt AACt Rq Rqmin Rqmax
ashe MAST1 40.37494 8.542105 0 1 0.468387 2.134985control
GAPDH =31.83283
SiRNAMastl MAST1 49.90142 16.49419 7.952084 0.004038 4.50E-04 0.036261
GAPDH 33.40723
 
Calculation of the percentage of Knock-down:
(% KD) = [1-2 44] x 100
Table A.3 Mast 1 SiRNA quantitative real-time PCR raw datas
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identification of S100A4 (Mts1) gene overexpression as a poor prognostic
marker for thyroid carcinoma."J Clin Endocrinol Metab 89(12): 6146-6154.
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